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INTRODUCTION TO THE THESIS
Cirrhosis of the liver is a chronic disorder resulting from a variety of known and
unknown aetiological factors, which lead to hepatocyte damage and death,
regeneration of remaining hepatocytes and progressive fibrosis in a sequential
manner. This ultimately leads to distortion of the architecture of the liver lobules.
The net result is liver cell dysfunction and an increase in the intrahepatic resistance
to blood flow. The latter, combined with alteration of portal blood flow and of
extrahepatic splanchnic vascular responsiveness characterizes portal hypertension.
Systemic and splanchnic vasodilatation seem to be prominent features of
decompensated hepatic cirrhosis and lead to a fall in the effective circulating blood
volume. This results in the activation of a cascade of compensatory events, which
include the RAS, release of AVP and heightened sympathetic nervous system
activity. Neuronal and humoral mechanisms, therefore, seem to be central to the
sodium and water retention, which occurs in cirrhosis of the liver. These
pathophysiological changes contribute to fluid retention and ascites.
The regulation of arterial tone in cirrhosis of the liver is complex and a multitude of
factors seem to be playing a part. The areas which have been explored in the past
include the role of endothelial-derived vasodilator agents, circulating vasodilator
agents which act on the vascular smooth muscle, and lack of response of the
vascular smooth muscle to vasoconstrictor agents.
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The last could in fact be a result of the first two factors. There is a paucity of data on
human tissues in the literature because of difficulty in acquiring larger distributory
arteries from cirrhotic patients for experimentation. Blood vessels acquired at OLT
offer the opportunity to study donor (normal) and recipient (cirrhotic) blood vessels
invitro under controlled standardized conditions (organ bath experiments).
The development of portal hypertension itself is followed by clinically important
sequelae. Enlargement of the spleen is an early and cardinal sign of portal
hypertension and it is difficult to make a diagnosis of portal hypertension without
the demonstration of splenomegaly. Factors which participate in the development of
splenomegaly include increase in portal pressure and splanchnic blood flow, and R-
E cell hyperplasia. However, the correlation of spleen size to these factors is not
entirely clear. The difficulty in interpreting the results of different studies in this area
of medicine is partly due to the lack of information about the accuracy of methods
used for determining spleen size and partly due to the paucity of data comparing the
different methods ofmeasuring spleen size including ultrasonography, CT scanning,
MRI and radionuclide studies. Radionuclides have also been used to quantify
splanchnic blood flows as well as liver function in the normal and patients with
chronic liver disease but there is again a scarcity of data in this regard.
The development of portal hypertension is associated with the opening up of porta-
systemic collateral shunts at different sites in order to decompress the portal
circulation. Clinically important shunt vessels develop in the oesophagus, stomach
and the duodenum. These assume varicose proportions and can rupture when the
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intravascular pressures rise above a threshold value. This can lead to potentially life
threatening haemorrhage. Shunting of blood to the systemic circulation is also a
contributory factor in hepatic encephalopathy.
Impairment of glucose tolerance and even the development of diabetes mellitus are
also consequences of cirrhosis and portal hypertension occurring in 10-40% of
patients. The prevalence of these abnormalities of glycaemic control increases as the
duration and severity of liver disease increases. Although, it is generally believed to
be a result of insulin resistance at the peripheral receptor sites, the pattern of insulin
secretion from the P cells of the pancreas is also believed to be altered in this form
of diabetes, particularly in the later stages. However, there are obvious problems in
quantifying insulin secretion from the endocrine pancreas as it undergoes significant
extraction during first pass through the normal liver and the pulse mass is lost to a
large extent. Measurements done at the peripheral vein site are therefore not an
accurate reflection of the quantum of insulin secretion over a period of time. TIPSS
used to treat complications of portal hypertension are reviewed at portographic
examinations and can be used to study the pattern of insulin secretion directly from
the portal vein. Although this complex investigation could only be done in a few
patients with relatively stable liver function, this human model can be used to study
the pattern of insulin secretion in the patients with different grades of severity of
liver disease and normal as well as abnormal glucose tolerance in hepatic cirrhosis.
A number of treatment strategies have been devised for prevention of bleeding and
control active bleeding from varices in the gastro-intestinal tract. These include
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endoscopic sclerotherapy, endoscopic variceal ligation, pharmacological measures
including P adrenoreceptor blocking agents and nitrates, surgical decompressive
shunts and TIPSS.
TIPSS is the most recent addition to the armamentarium of treatment modalities.
Although it is a highly effective of treatment, there are obvious problems in that
procedure related and short and long-term complications limit its acceptability.
Procedure related complications include intraperitoneal bleeding and subcapsular
haematoma in the liver. The main longer-term problems relate to sepsis,
precipitation of hepatic encephalopathy and SI and occlusion. A number of shunt
and patient related factors have been assessed as predictors of SI and these include,
age and sex of patients, the liver functions, pre- and post-stent insertion portal
pressures and the diameter of the stent. The role of diabetes mellitus, which has been
shown to encourage stenosis in vascular stents placed elsewhere in the body, has not
been assessed in TIPSS.
Accordingly, the aim of this thesis was to explore the following aspects of hepatic
cirrhosis and portal hypertension.
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AIMS OF THE THESIS
1.1 TO STUDY THE PATHOPHYSIOLOGIC MECHANISM OF VASCULAR
HYPORESPONSIVENESS IN HEPATIC CIRRHOSIS.
• The aim in these experiments was to investigate the role of NO release in
modulating a-adrenoceptor mediated contraction in hepatic cirrhosis.
1.2 TO STUDY CLINICAL SEQUELAE OF PORTAL HYPERTENSION DUE
TO HEPATIC CIRRHOSIS.
These were the areas of study in relation to clinical sequelae:
• The clinical aspects of splenomegaly and its relation to portal
haemodynamic factors in portal hypertension due to hepatic cirrhosis.
• The role of radionuclides in measuring spleen size and assessing liver
function in hepatic cirrosis and portal hypertension.
1.3 TO STUDY THE PATTERN OF INSULIN SECRETION IN CIRRHOTIC
PATIENTS WITH TIPSS AND THE IMPACT OF DIABETES MELLITUS
ON TIPSS FUNCTION.
• The pattern of pulsatile insulin secretion in portal vein in patients suffering
from hepatic cirrhosis using a TIPSS inserted model was studied. This
model should help study pattern of insulin secretion in different stages of
hepatogenous diabetes mellitus, ie., impaired glucose tolerance and frank
diabetes mellitus.
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• The effect of diabetes mellitus on the efficacy of TIPSS in the treatment of
patients suffering from portal hypertension has been studied.
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ABSTRACT OF THESIS
Cirrhosis of the liver impairs liver function and causes portal hypertension. It leads
to many abnormalities including splenomegaly, GOV, portasystemic shunting of
blood and widespread circulatory changes. Metabolic changes include diabetes
mellitus. TIPSS, a recent treatment for portal hypertension is limited by the frequent
occurrence of stent occlusion. I have investigated several of these features of
cirrhosis and portal hypertension, and this thesis comprises the results of these
investigations:
1: The role of NO as a mediator in the hyporesponsiveness of hepatic arteries in
cirrhosis is investigated, invitro noting the effect of iNOS inhibition on vascular
contractility. Result: No difference between the contractile response of cirrhotic and
non-cirrhotic blood vessels to phenylephrine was noted with or without iNOS
inhibition. Conclusion: iNOS activity does not modulate cc-adrenoceptor mediated
contractility in hepatic cirrhosis.
2a: To assess the role of clinical palpation in diagnosing splenomegaly in hepatic
cirrhosis and to determine the value of abdominal ultrasound in assessing spleen
size. Ultrasonography is compared with radionuclide imaging in measuring spleen
size. Spleen size has also been related to peripheral blood features of hypersplenism,
severity of liver disease, size of GOV and with portal haemodynamic measurements.
Results and conclusions: Clinical palpation is an insensitive tool in assessing
spleen size. There is a good correlation between spleen weight and ultrasonically
determined length of spleen. Ultrasonography and radionuclide imaging give
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comparable results in measuring spleen size. There is a good correlation of spleen
size with portal vein blood flow volume but not with PPG and azygos vein blood
flow volume. Spleen size also correlates well with the size ofGOV and a history of
variceal bleeds. Spleen size also correlated with the peripheral WBC count but not
haemoglobin concentration and platelet count indicating that hypersplenism in portal
hypertension affects the different formed elements of the blood to different degrees.
2b: SPECT of spleen has been used to assess severity of liver disease in hepatic
cirrhosis. Results: Spleen uptake of radioisotope per unit volume (% injected dose
of radioisotope/ml.) increases and the L/S uptake ratio diminishes as the liver
disease worsens. There is also a negative correlation between spleen uptake per unit
volume and the size of spleen. Conclusion: SPECT of the spleen can be used to
assess liver function in patients with liver disease.
3a: To measure the frequency of pulsatile insulin secretion in portal vein of patients
suffering from hepatic cirrhosis. The frequency and amplitude of secretory bursts in
the portal vein has been compared to that in the systemic circulation in order to see
the impact of hepatic extraction and dilution on the peripheral delivery of insulin.
The impact of hyperglycaemia on secretory pattern of insulin has also been assessed.
Results and Conclusions: Direct sampling from the portal vein in human cirrhotic
subjects establishes an interpulse interval of ~ 5 minutes. It also shows that the
majority of insulin is secreted as bursts and the apparently preferential hepatic
extraction of pulses leads to post-hepatic delivery of smaller amount of insulin in
discrete bursts.
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3b:To assess the role of diabetes mellitus in producing TIPSS insufficiency. Results
and conclusions: Diabetes mellitus is common in patients undergoing TIPSS and
leads to early shunt insufficiency.
26
SECTION 2
VASCULAR HYPORESPONSIVENESS IN PORTAL
HYPERTENSION DUE TO HEPATIC CIRRHOSIS
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2.1 INTRODUCTION
Chronic increases in systemic and splanchnic blood flow have been observed in the
hyperdynamic circulatory state of portal hypertension in animals and humans.
Peripheral vasodilatation seems to initiate the development of decreased systemic
vascular resistance and mean arterial pressure, plasma volume expansion, elevated
splanchnic blood flow and elevated cardiac index that characterizes this state
(Colombato et al, 1992).
The severity of the haemodynamic alterations increases as cirrhosis worsens, with
patients with mild disease exhibiting only mild changes and a small increase in
plasma volume (Eisenberg, 1956; Ryan et al, 1996). As the disease advances, the
circulatory abnormalities, accompanied by increased water retention and increased
plasma hormone concentrations become more pronounced (Lieberman and
Reynolds, 1967; Willet et al, 1985). These changes may lead to severe
complications, including renal failure (hepatorenal syndrome), which is associated
with high mortality (Rahman et al, 1992).
Several mechanisms including increased concentrations of circulating vasodilators,
increased endothelial production of local vasodilators and decreased vascular
responsiveness to endogenous vasoconstrictors have been implicated in the
production of peripheral vasodilatation. The last mechanism is likely due to the
effect of the first two components. Alternatively, receptor and post receptor defects
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in signal transduction could be operative in the impairment of responsiveness to
vasoconstrictors in cirrhosis, resulting ultimately in lowering of vascular tone.
2.1.1 Systemic vasodilatation
2.1.1.1 Circulating vasodilators
In portal hypertension, there is an increase in both endothelium-dependent and
endothelium-independent vasodilators. The rapid reversal of haemodynamic
derangement following liver transplantation (Woods et al, 1987), normal function of
transplanted kidneys from cirrhotic donors (Koppel et al, 1969), and the induction of
a hyperkinetic state by cirrhotic plasma (Loyke and Hoobler, 1982), strongly
implicate a blood borne vasodilator. A number of substances have been implicated
as mediators of vasodilatation in cirrhosis of the liver, such as those normally
metabolized by the liver and present in abnormal concentrations in advanced liver
disease. These include vasoactive intestinal polypeptides (Hunt et al, 1979),
prostacyclins (Stitzman et al, 1989), endotoxins (Triger et al, 1978; Lumsden et al,
1988), glucagon (Benoit et al, 1984 ; Lee et al, 1988), and NO (Claria et al, 1992;
Stark et al, 1992). There is also evidence of over production of vasodilator
substances (Hortnagl et al, 1984; Kravetz et al, 1987). Some substances, normally
inactivated or excreted by the lungs, have also been thought to bypass lung tissue in
the presence of pulmonary arteriovenous shunts (Rydell et al, 1956; Berthelot et al,
1966; Hansoti et al, 1966). Other mechanisms invoked to account for the greater
presence of vasodilator substances in the systemic circulation include intrahepatic
(Huet et al, 1982), portacaval (Lebrec et al, 1983) and portopulmonary shunts
(Shaldon et al, 1961 ), these shunts providing bypasses of hepatic tissue.
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2.1.1.2 Increased endothelial production of vasodilators: The role ofNO.
There is increasing evidence for a major role for the endothelium in the maintenance
of basal vascular tone and the development of systemic splanchnic vasodilatation in
portal hypertension. The endothelial cells synthesize and release potent vasoactive
substances such as prostacyclin, endothelin I, NO, angiotensin II, C-naturetic
peptide, platelet activating factor, substance P and histamine (Suga et al, 1992;
Casadevall et al, 1993; Ross, 1993). These substances act locally on the vascular
smooth muscle cells in a paracrine fashion.
NO which was peviously known as endothelial-derived relaxing factor, is
synthesized from L-arginine by the enzyme NOS, which has at least two isoforms: a
constitutive (calcium-dependent) form termed eNOS, and an endotoxin- or cytokine-
inducible form termed iNOS, in different cell types. This enzyme mediates its potent
vasodilatory action on vascular smooth muscle cells through soluble guanylate
cyclase.
There is some evidence that elevation of NO synthesis is essential to the
development of portal hypertension, and treatment with L-NNA, a competetive
inhibitor ofNOS, prevented the development of peripheral vasodilatation, decreased
systemic arterial pressure, and plasma volume expansion in portal vein ligated rats
(Lee et al, 1993). Similarly, chronic administration of L-NAME, another inhibitor of
NOS, has been shown to delay splanchnic vasodilatation, development of collaterals
and decrease splanchnic blood flow in portal vein ligated rats (Garcia-Pagan et al,
1994). In portal vein ligated rats, isolated aortic rings have also demonstrated
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increased relaxation to acetylcholine, an endothelial agonist, compared with sham
controls. This increased response to acetylcholine was partly reversed by L-NAME
(Karatapanis et al, 1994). Whether the production of NO is the primary stimulus in
the development of vasodilatation or a subsequent phenomenon that results from
shear, and secondarily contributes to increased flow, has yet to be determined.
It has been hypothesized that the chronic endotoxaemia in portal hypertension and
cirrhosis may upregulate iNOS in vascular smooth muscle cells, thus causing the
increased NO production that leads to splanchnic vasodilatation (Vallance and
Moncada, 1991). The resultant increase in NO release also explains the raised
urinary nitrates and nitrites (Bird et al, 1993; Hori et al, 1995) and cGMP levels in
cirrhosis (Schneider et al, 1994). Furthermore, direct measurements confirmed that
NO concentrations were increased in the splanchnic circulation in cirrhosis (Battista
et al, 1997).
TNF-oc may also play an important role in the vasodilatation by upregulating iNOS.
Treatment with anti-TNF-oc polyclonal antibodies has been shown to ameliorate the
hyperdynamic circulation in cirrhosis in animals (Lopez-Talavera et al, 1995, 1996).
Induction of iNOS in hepatic cirrhosis has not been proven and the relative
contributions of the constitutive and inducible forms of NOS are still under
investigation. Data from humans in this area is very limited (Smith et al, 1993;
Scheppke et al, 1997). This has prompted the present investigation to be undertaken
on hepatic arteries obtained from human subjects suffering from hepatic cirrhosis of
advanced stage and undergoing OLT.
31
2.1.1.3 Decreased responsiveness to vasoconstrictors
Vascular tone is regulated by a complex interaction between endogenous
vasodilators and vasoconstrictors. A decreased response to vasoconstrictors may
therefore contribute to vasodilatation and thereby to a hyperdynamic circulation. In
portal hypertension, invitro hyporesponsiveness to the endogenous vasopressors
norepinephrine, AVP and angiotensin II has been reported to contribute to the
hyperdynamic circulation (Sieber and Groszman, 1992a).
The hyporeactivity of blood vessels to pressor agents appears to be mediated partly
by NO. In portal hypertensive rats, inhibition of NO in isolated, perfused superior
messenteric artery has been shown to prevent the development of vascular
hyporeactivity to the vasoconstrictors nor-epinephrine and AVP (Sieber and
Groszman, 1992b).
The situation in human subjects with portal hypertension is less clear. This is partly
due to paucity of suitable vascular tissue for invitro experimentation and small
numbers of subjects being studied in invivo. Invitro experimentation on tissues
provides standardized conditions while eliminating the confounding effect of factors
like central and autonomic nervous systems, circulating endogenously produced
hormones and intravascular volume mismatches between individuals. Such
experiments are possible in centres where OLT is being done and donor (control)
and recipient (cirrhotic) blood vessels are available for comparative analysis.
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2.2 STUDIES OF INVITRO RESPONSIVENESS OF HUMAN HEPATIC
ARTERIES IN PATIENTS SUFFERING FROM HEPATIC CIRRHOSIS
2.2.1 Methods to study isolated organ preparations invitro
The Organ Bath System
The full system for studies in isolated organ preparations is termed the organ bath
system, and has three main elements. The first is an arrangement, which provides
standardised, optimal invitro conditions for the preperation. This is the biological
system. It consists of the glass organ bath (see description below and Figure 2.1),
the physiological salt solution, thermostatic control (to keep the saline at a constant
temperature), provision of oxygen and carbon dioxide aeration of the suspended
tissue and physiological salt solution, and the test substance itself. The second is a
measuring device for recording the change in tension in the smooth muscle (test
organ) following the appropriate stimulus. This device comprises of a transducer,
amplifier and the recording instrument. The third is the transmission system, which
forms the mechanical link between the first two components.
The organ bath comprises of a double walled glass chamber in which the test
preparation is suspended in physiological saline (Figure 2.1). The saline is
maintained at a constant temperature by the flow ofwater of the correct temperature,
through the outer cavity. The water used for this purpose is maintained at a constant






Figure 2.1: Experimental set-up for the measurement of tension of human hepatic
artery rings without endothelium. This double jacketed tissue bath was used for all
experiments, where recordings of isometric contractions were made. The volume of
the bath is 10 ml.
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Test preparations are usually washed by overflow, which means that the preparation
is never without the physiological solution it needs. The two main purposes of
washing are to provide fresh physiological solution and to wash out test compounds
that have been added during the study. Since overflow washout is actually a dilution
process, an excess volume of fresh solution must be added, i.e. about 5 times the
volume of the inner bath. The preparation is usually washed twice. The volume of
saline required to change the contents of a particular organ bath can be calculated by
adding a dye to the full bath and measuring the volume of fresh water that has to be
passed through before the contents are completely clear again. It is essential that the
temperature of the washout solution does not vary by more than ± 0.5° C from the
solution already in the inner bath. The reservoir of physiological saline used for
washouts is maintained at a constant temperature with the help of thermostatic
mechanisms and should also be constantly aerated with 95% O2 +5% CO2 passed
through a large frit, or pumped in directly, in which case the reservoir should also be
stirred (e.g. with a magnetic stirrer) in order to ensure homogeneity.
The inner organ bath chamber can have a volume of 50 mis. If only a small quantity
of the test substance is available, however, a smaller vessel should be used, e.g. 5 or
10 mis. It is then particularly important to measure the dose precisely, and to add it
to the bath in exactly the same way each time. A micropipette or a Hamilton syringe
is sufficiently accurate to measure such small volumes. Although baths with a
relatively large volume such as 50 mis require far more physiological solution and
test substance, the possibility of error in measuring the dose is less, as the volumes
involved are greater.
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The lower end of the organ preparation can be attached to a glass hook fused to the
floor of the inner bath, although it is quite difficult to loop the thread or wire clip
around it successfully, because the preparation has to be kept relatively taut, so that
it will not detach itself. The wire loop at the top end of the tissue is connected to the
transducer to provide transmission, taking care not to overstretch the preparation.
The organ bath must be deep enough for the organ and the wire clip to remain
completely submerged in the physiological solution at all times.
Physiological salt solution
The current experimentation was done using KHS as the physiological solution to
preserve recipient and donor hepatic arteries during transportation from the
transplant theatre to the laboratory and during experimentation.
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The constituents and preparation of the solution is shown in Table 2.1 below.
pH 7.4











Working solutions of KHS were prepared from stock solutions 'A' and 'B' as
required. The constituents of these solutions are shown in Table 2.2 (next page).
38
Table 2.2: Constituents of Solutions A and B.
Solution a Solution B
Constituent Quantity Constituent Quantity
Deionised water 2 litres Deionised water 2 litres
NaCl 276.8 gm NaHCOs 84 gm
kc1 14.0 gm kh2 po4 6.4 gm
MgS04. 7H2 O 11.6 gm
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Final KHS
This was prepared by adding together the following constituents.
Deionised water 1.8 litres
Solution A 100 ml
Solution B 100 ml
CaCl2. 6H20 1.1 gm
Glucose 4.2 gm
Preparation of other Stock solutions and calculation of volume to be added in the
The following stock solutions were prepared using formula weights. Stock solutions
of PE, L-NNA and D-NNA were prepared in deionized water and frozen in I ml.
Aliquots. These were thawed as required and any residue was discarded at the end of
experiment.
1) L-NNA:
Formula weight = 219.2
219.2 gm in 1 litre = 1M
219.2 mg in 1 ml = 1 M
219.2 mg in 10 ml = 0.1 M
21.92 mg in 10 ml = 0.01 M (Stock Solution).
2) D-NNA:
Formula weight = 219.2
219.2 gm in 1 litre =1 M
bath.
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219.2 mg in 1 ml
219.2 mg in 10 ml
21.92 mg in 10 ml
= 1 M
= 0.1 M
= 0.01 M (Stock solution).
3) PE:
Formula weight = 203.7
203.7 mg in 1 ml = 1 M
203.7 mg in 10 ml =0.1 M
20.37 mg in 10 ml = 0.01 M (Stock Solution)
4) KC1:
Formula weight = 74.55
74.55 gm in 1 litre =1 M
7.455 gm in 100 ml =1 M
14.91 gm in 200 ml = 1 M
29.820 gm in 200 ml = 2 M
The volume of KC1 to be added to the bath chamber containing the test preparation
was calculated as follows:
If 2M KC1 stock solution is to be added to an organ bath of 10 ml volume to give a
concentration of 100 mM.
If Ci = concentration of stock solution
Vi = volume of stock solution added to the bath
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C2 = Final concentration of solution in the bath
V2 = volume of the bath (=10 ml)
Apply the formula Ci x Vi = C2 x V2
Where Ci = 2M
V, = ?
C2= 100 mM=0.1 M
V2= 10 ml
V, = C7 x V,
C,
V1= O.lMx 10 ml = 0.5 ml = 500 p litre
2M
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2.2.2 NOS inhibition and its impact on oc-adrenoceptor mediated contraction
invitro
2.2.2.1 Background:
Patients with cirrhosis show impaired responsiveness to vasoconstrictors, which is
maintained invitro (Hadoke PWF and Hayes PC, 1997). The reason for this is not
clear, although various mechanisms have been proposed. These include the effect of
vasodilatory agents (Loyke et al, 1986), receptor down-regulation (Gerbes et al,
1985) or a post-receptor defect (Murray and Paller, 1985), (for details see section
2.1-2.113). Generation of NO by iNOS in vascular smooth muscle cells may
contribute to impaired contractile function in arteries from patients with cirrhosis.
This is controversial, as studies of isometric contraction in humans have produced
conflicting results (Smith et al, 1993; Schepke et al, 1997).
2.2.2.2 Aim:
The study aimed to determine whether the release of NO from vascular smooth
muscle cells modulates a-adrenoceptor-mediated contraction of endothelium
denuded hepatic arteries isolated from patients with cirrhosis.
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2.2.2.3 Materials and Methods:
Vessel Acquisition and Preparation
For the study of vascular reactivity in splanchnic vessels isolated from patients with
cirrhosis, hepatic arteries were obtained from (non-cirrhotic) liver donors (n=8) and
(cirrhotic) recipients (n=9) at the time ofOLT at the SLTU at the Royal Infirmary of
Edinburgh, Scotland. The cause of death of donors and aetiology of cirrhosis in
recipients are given in Table 2.3.
During retrieval of the healthy liver from an organ donor, the surgical team routinely
collects the entire hepatic artery and the coeliac axis. These are stored in a
preservative, UWS (UWS; NPBI International BV, Emmer-Compascum, The
Netherlands; and Du-Pont Pharmaceuticals Ltd., Herts, UK.) at 4° C with the donor
liver. At the end of OLT, after anastomoses of the graft, the residual hepatic artery
samples are usually discarded and so become available for functional analysis. As
the (cirrhotic) liver removed from the recipient is fixed in normal saline for
histological analysis, recipient hepatic arteries were dissected directly from the
explanted recipient livers, prior to fixing immediately after it had been removed
from the patient.
Donor and recipient hepatic arteries obtained from the transplant theatre were placed
immediately in fresh, ice-cold, oxygenated KHS and transported to the laboratory
for functional analysis. This provided donor hepatic arteries which had been stored
in UWS for up to 16 hours and recipient hepatic arteries, obtained immediately
following removal from the patients.
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Table 2.3: Causes of death in liver donors and aetiology of cirrhosis in
recipients.
Donor No. Recipient No.
Sub-arachnoid haemorrhage 3 Primary Biliary Cirrhosis 6
Intracerebral haemorrhage 3 Alcoholic Liver Disease 1
Head injury 1 Primary Sclerosing Cholangitis 1
Road Traffic Accident 1 Autoimmune Hepatitis 1
Total 8 Total 9
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Ethical approval for use of human tissues was obtained from the Lothian Research
Ethical Committee and the arrangements were approved by the United Kingdom
Transplant Support Services Authority.
These arteries were carefully cleaned of adherent connective tissue and fat, and if
necessary, were stored in the refrigerator at 4° C in freshly prepared oxygenated
KHS solution. Whenever possible, experiments were performed immediately after
the retrieval of the arteries. Such vessels are generally devoid of endothelium and
removal of any residual endothelium was ensured by rubbing the luminal surface of
each vessel with a blunt probe, while the rings were kept completely immersed in
KHS on a petri-dish.
Experimental Protocol
Two rings (2 mm in length) were prepared from each artery and mounted in parallel
on two intraluminal stainless steel wire hooks in 10 ml. organ bath chambers
(described in section 2.2.1) containing KHS (composition as shown above) at 37°C
continuously perfused with 95%C>2 and 5%CC>2. The lower hook was fixed to the
base of the organ bath, whilst the upper hook was attached to a force displacement
transducer (Grass FT-03) connected to a computerized data acquisition system (Dr H
Brash, Department of Medicine, Royal Infirmary of Edinburgh) for the measurement
of isometric force.
The arterial rings were then gradually stretched to their optimum resting force
[previously shown to be 4g (Hadoke et al., 1998)] and allowed to equilibrate for 45-
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60 min. During equilibration, the tension was gradually adjusted and the contents of
the organ baths replaced at frequent intervals. After equilibration, the viability and
reproducibility of contraction of each ring was tested by stimulating with a single
concentration of lOOmM KC1. Rings were washed with KHS once the contraction
was stabilized. The procedure was repeated 3-4 times until reproducible, sustained
contractions were obtained.
One ring from each artery was incubated for 40min with the NOS inhibitor L-NNA;
(lO^M), whilst the other was incubated with its inactive isomer D-NNA; (lO^M).
Cumulative concentration response curves were then constructed for PE; (10"9-3xl0"
4M) and KC1; (2.5-120 mM).
L-NNA, D-NNA and PE were obtained from Sigma, Poole, Dorset, UK.
Sample traces of blood vessel contractility are shown in Appendix 1-1V.
Statistical analysis:
Results are expressed as mean ± SEM; n represents the number of subjects.
Maximal contractions are given in grams and as a percentage of maximum
contraction to KC1 to control for variation in the size of the arterial rings.Sensitivity
(pD2) values for agonists were determined for individual concentration-response
curves using a curve-fitting programme (Fig P., Biosoft, Cambridge, U.K). M.C.
contraction and sensitivity (pD2) values were compared using Student's unpaired t-
test and values were considered significant when p<0.05.
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2.2.2.4 Results:
For each artery, mean values were calculated from the results of 2 rings, where
appropriate. The maximum contractile responses of the receptor-dependent agonist
(PE) are given as gms. and as a percentage of the maximum contraction to KC1 (to
minimize any discrepancy in the sizes of the arterial rings (Lew and Angus, 1992)).
Contractile responses to receptor independent agonist (KC1) are expressed in gms.
(Table 2.4).
Denuded hepatic arteries obtained from non-cirrhotic donors and cirrhotic recipients
contracted in a cumulative concentration-dependent way, when exposed to receptor-
dependent agonist (PE) and receptor-independent agonist (KC1).
The maximum contractile response to PE in RHA (M.C. 9.33±1.09 g, n=9) was
similar to that of DHA (M.C. 10.46+1.71 g, n=8, p=0.58). Similarly, the contractile
response of RHA and DHA was not dissimilar when expressed as a percentage of
maximum contractile response to KC1 (M.C. 122.44+11.16% and 155.51+17.26%;
p=0.20; RHA and DHA respectively). The pD2 values for this agonist between RHA
(5.26±0.22) and DHA (5.67±0.31) were also similar (p=0.40) (Table 2.4), despite a
suggestion that PE caused a smaller, less sensitive, response in arteries from
(cirrhotic) recipients, compared with (non-cirrhotic) donors (Figure 2.2).
The denuded hepatic arterial rings obtained from the (cirrhotic) recipients and (non-
cirrhotic) donors, contracted in a cumulative concentration-dependent way, when
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exposed to PE and KC1, whether incubated with L-NNA or D-NNA. Incubation of
these denuded arterial rings with NOS inhibitor L-NNA had no effect on basal
resting tone set up during equilibration, in both DHA and RHA. Furthermore,
incubation with L-NNA did not alter the response of either DHA (Figure 2.3) or
RHA (Figure 2.4) to PE (Table 2.5). Cumulative concentration response curve
produced in response to KC1 in DHA and RHA is shown in Figure 2.5. This curve
shows that the receptor independent contraction to KC1 is maximal at 100-120 mM
KC1 concentration.
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Table: 2.4: PE response comparing DHA and RHA.
RHA (n=9) DHA (n=8) p value
M.C.(g) 9.33 ±1.09 10.46 ± 1.71 0.58
M.C. (%KCI) 122.44 ± 11.16 155.51 ± 17.26 0.20
pd2 5.26 ± 0.22 5.67 + 0.31 0.40
M.C. to KCI (g) 7.81 ± 1.10 7.2 ± 1.32 0.72
Results are expressed as mean ± s.e.m. in (n) arteries.
M.C. = Maximum Contraction
pD2 = -log EC 50, where EC 50 is the concentration of the test substance in the







Figure 2.2: Cumulative concentration-response curves produced in response to PE
by DHA (□) and RHA (v). Responses are given as mean + s.e.m. and expressed as a
percentage of the maximum contraction induced by KC1. For n values see Table 2.4.
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-Log[PE]
Figure 2.3: Cumulative concentration-response curves produced in response to PE
by DE1A after incubation with D-NNA (□) and L-NNA (■). Responses are given as
mean ± s.e.m. and expressed as a percentage of the maximum contraction induced
by KCE For n values see Table 2.4.
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Figure 2.4: Cumulative concentration-response curves produced in response to PE
by RHA after incubation with D-NNA (□) and L-NNA (v). Responses are given as
mean ± s.e.m. and expressed as a percentage of the maximum contraction induced
by KCE For n values see Table 2.4.
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Figure 2.5: Cumulative concentration response curves produced in response to KC1
by DHA (O) and RHA (M). Responses are given as mean ± s.e.m. and expressed as

































Resultsareexpressedmean±s. .m.in( )rt ries M.C.=aximumContraction pD2=-logEC50
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2.2.2.5 Discussion:
The present investigation has studied vascular responsiveness of endothelium
denuded hepatic arteries in portal hypertension due to cirrhosis of the liver in human
subjects. The role of iNOS in modulating vascular contractility has been specifically
studied.
It has been proposed that the impaired pressor response to a-adrenoceptor agonists
in patients with advanced cirrhosis is due to inability of vessels to respond to
constrictor agonists. The persistence of impaired contraction exvivo in arteries
isolated from animal models suggests that this could be due to an intrinsic defect in
the cells of the vessel wall rather than being secondary to the action of a circulating
vasodilator substance (reviewed in Hadoke and Hayes, 1997). The current
investigation found no difference in the a-adrenoceptor mediated, nor receptor
independent contractile response between endothelium denuded hepatic arteries
obtained from cirrhotic and normal humans (Table 2.4). This indicates that the
impaired excitation-contraction coupling in, or the release of vasodilators from the
vascular smooth muscle cells of hepatic arteries, are not responsible for the impaired
pressor response associated with this condition and that circulating vasodilators or
endothelium derived factors are probably active invivo in modulating vascular
responses to physiological stimuli.
Hepatic arteries were used in this study, as they belong to a vascular territory
(splanchnic), which is known to be dilated in cirrhosis (Iwao et al, 1997). They
contracted in a stable reproducible manner when exposed to PE and KC1 invitro.
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Although, hepatic arteries with an intact endothelium have been obtained from
hepatectomy specimens (Jeng et al, 1996), loss of endothelium is a consistent
finding in all investigations using arteries from the transplant theatre (Smith et al
1993; Heller et al, 1996; Schepke et al, 1997). It was also anticipated that
preservation in UWS would not alter the contractile function of donor hepatic
arteries. It has been shown already that function of the rat mesenteric arteries is
unaltered after 3 days in a physiological salt solution (Mclntyre et al, 1998) and
UWS has been shown to preserve the contractile function of human hepatic arteries
(Jeng et al, 1996).
A defect in receptor-mediated contraction may occur as a result of either receptor
down regulation or altered post-receptor signal transduction. In the current study,
constriction in response to the selective cti-adrenoceptor agonist PE was not altered
in hepatic conduit arteries from transplant recipients. As the ai-adrenoceptor
subtype has been shown to mediate contraction in the hepatic artery (Vagianos et al,
1990), the results of the present investigation suggest this receptor is not down
regulated in hepatic arteries of patients with cirrhosis. Normal receptor function in
arteries from animals with cirrhosis or portal hypertension (Liao et al, 1994)
suggests that the impaired contraction was the result of a post receptor defect in
signal transduction mechanisms. Such a defect in the hepatic artery was not
indicated in the present study as neither receptor mediated (PE) nor receptor
independent (KC1) contractions were impaired.
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Furthermore, the inhibition of iNOS by incubation with L-NNA made no difference
to the contractile response in the recipient (cirrhotic) and donor (normal) hepatic
arteries, suggesting that the release of NO by the vascular smooth muscle cells does
not occur in human hepatic arteries as this would have resulted in reduced responses
to both receptor-dependent and receptor independent vasoconstrictors (Jeng et al,
1996). This is consistent with other results presented recently where hepatic arteries
isolated from the transplant theatre were used (Schepke et al, 1997). The loss of
endothelium from the vessels in the current study prevented investigation of the role
ofNO released by eNOS.
These results indicate that future investigations should attempt to clarify the role of




These results indicate that the release of NO from the smooth muscle cells of the




SPLENOMEGALY IN PORTAL HYPERTENSION
DUE TO HEPATIC CIRRHOSIS
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3.1 INTRODUCTION
Cirrhosis of the liver is a chronic disorder which leads to portal hypertension and
hepatic failure in the end stage of the disease. Portal hypertension in hepatic
cirrhosis results mainly from increased resistance to portal blood flow and leads to
the development of porto-systemic collaterals, which partly decompress the portal
circulation. At the same time, the portal venous inflow through the splanchnic
circulation increases and thus maintains the elevated portal pressure and also
compensates, to some extent, for the loss of portal blood flow through collaterals.
The development of a collateral circulation is partly responsible for hepatic
encephalopathy and leads to gastro-intestinal bleeding from GOV and portal
gastropathy.
3.1.1 Splenomegaly:
Portal haemodynamic changes in cirrhosis lead to the development of splenomegaly.
This occurs earlier in portal hypertension than the development of GOV and care is
needed in diagnosing portal hypertension without the demonstration of
splenomegaly (Hayes PC, 1997).
The clinical diagnosis of splenomegaly itself is difficult, because the organ has to
enlarge considerably before becoming palpable and therefore more sensitive
methods to measure spleen size are required. A number of techniques have been
used to measure spleen size and these include abdominal radiography (Martin,
1937), ultrasonography (Koga and Morikawa, 1975; Niederan et al, 1983), CT
(Heymsfield et al, 1979), MRI (Williams et al, 1985) and radionuclide scanning
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(Rollo et al, 1970; Mut et al, 1988; Strause et al, 1984). The accuracy and
comparability of these techniques is not well established as relatively few studies
have investigated their comparability and only limited numbers of patients have
been studied (Meek et al, 1984).
3.1.1.1 Clinical examination of the Spleen:
Clinical examination of the spleen, although seemingly a simple bedside diagnostic
tool, requires careful technique and the recognition of its limitations. Palpability of
the spleen depends upon a number of factors including size of the organ, its position,
laxity of the ligaments which hold it in place, the thickness and tension of the
abdominal muscles, obesity and the presence of ascites. In practice, a palpable
spleen is almost always enlarged, but an impalpable spleen is not necessarily of
normal size. The increasing precision of radiological techniques however, does not
diminish the value of bedside methods of detecting splenomegaly.
Clinical examination is best carried out from the right side of the patient. Palpation
is begun in the right iliac fossa to avoid missing a grossly enlarged spleen and the
right hand is advanced towards the left hypochondrium. Minimal degrees of
palpable enlargement are detectable by placing the hand in the left loin to lift the
lower aspect of the rib cage forward and then attempting to feel for the lower pole or
the medial border of the minimally enlarged spleen. This manouvre displaces the
spleen forward and aids it to become palpable. Clinical palpation of spleen is a skill
learnt with great practice. Percussion over the lower ribs may prove to be a useful
adjunct. The long axis of the spleen lies along the 10th rib and with enlargement,
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extends medially and downwards (Figure 3.1). Splenic dullness to percussion, in
health rarely extends further forwards than the mid-axillary line. A change in the
percussion note in the anterior axillary line on inspiration with the patient lying
supine may indicate early enlargement (Castell, 1967).
3.1.1.2 Structure of the spleen
Gross anatomy and size
The spleen is an important lymphoid organ. Its size is very variable, ranging from 35
gms. in elderly females to 280 gms. in young adults (Krumbhaar and Lippincott,
1939; Deland, 1970; Myers and Segal, 1974). At birth, the spleen is about 4.5 cm. in
length, 2.5 cm. wide and 1.5 cm. thick, and the mean weight is 11 gms. By the age
of one year the weight is 15-25 gms; by 5 years it is 40-70 gms. and by 10 years it is
80-100 gms. (Lewis, 1987). It reaches its maximum weight at around puberty, when
it has a mean weight of about 150-180 gms. (Hanley and Ludlam, 1997). It tends to
become lighter thereafter. It is slightly heavier in the adult male than in the female.
The size of the spleen as assessed by plain X-Rays of the abdomen, ultrasonography,
CT scanning, MRI and scintigraphic radionuclide studies has revealed, that the
normal adult spleen is 8-11 cms. long, 4.5-6.0 cms. wide and has a volume of less
than 250 mis. Spleens larger than this are usually palpable.
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Figure 3.1: An early physical sign of splenic enlargement; extension of splenic
dullness anterior to the mid-axillary line along the line of the 10th rib.
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The size of spleen however, cannot be the only factor to determine palpability, as the
organ can be palpable in normal young adults without being enlarged (Berris, 1966;
Ebaugh and Mclntyre, 1979) and a grossly enlarged spleen may not be palpable.
Fischer (1970) observed that 50% of moderately enlarged spleens weighing 600 to
750 gms. and 20% of greatly enlarged spleens weighing 900 to 1600 gms. could not
be palpated. The presence of ascites makes clinical detection even more difficult
(Fischer, 1970). This highlights the importance of radiological aids like abdominal
ultrasonography, CT scanning, MRI and scintigraphy in verifying and
supplementing the findings of clinical examination.
Histology
The spleen has a complicated structure. It consists of a connective tissue framework,
vascular channels, lymphatic tissue, lymph drainage channels, and cellular
components of the haematopoeitic and R-E systems. Histologically, there are two
main components: (a) the white pulp; and (b) the red pulp. The white pulp consists
mainly of peri-arteriolar lymphoid sheaths and the adjoining follicles (Malpighian
bodies) which contain a germinal centre and are structurally similar to lymphoid
follicles. The red pulp consists of sinuses, lined by macrophages and pulp cords. The
outer capsule of connective tissue framework consists of collagen tissue covered by
serous endothelium. From this, come off a large number of trabeculae which extend
into the pulp, carrying blood vessels and autonomic nerves. The spleen is a very
vascular organ and derives its arterial blood supply from the splenic artery which is
a branch of the coeliac axis and thence through the trabecular arteries, into the
central arteries which are sited in the white pulp. These latter vessels run into a
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central axis of the periartiolar lymphatic sheaths; and give off many arterioles and
capillaries, some of which terminate in the white pulp whilst others go into the red
pulp. There they either connect directly with the sinuses and thence, via the
collecting vein, to the trabecular veins or they first pass into the cord spaces before
passing into the sinuses (Figure 3.2).
Thus, as the blood flows through the spleen it comes into contact with the reticular
fibres and with the reticulo-endothelial macrophages which lie in the interstices of
the reticular mesh. The splenic vein drains the blood into the portal venous
circulation.
Bloodflow in the spleen
The spleen seems to have two blood flow systems (closed and open), whereby a
rapid and slow circulation occurs through the organ (Fig. 3.2). The slower
component is the usual pathway under normal circumstances, and several passages
of the whole blood volume through it occur during a 24 hour period. In
splenomegaly, the blood flow through the spleen can reach 20 percent of the blood
volume per minute. At the same time, increased pooling of blood also occurs in the
enlarged organ. (Harris et al, 1958; Christensen, 1973).
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Figure 3.2: Diagramatic illustration of the circulation of the spleen. The blood
passes either directly into a sinus (C, closed system) or first into the cord spaces in
the red pulp (O, open system).
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3.1.1.3 Function:
Cell sequestration, phagocytosis andpooling in the spleen
The spleen has a remarkable ability to aid in the maturation of red blood cells for
recirculation and also to remove from the circulation effete or damaged cells as well
as foreign matter. This occurs via three different mechanisms: sequestration which
is a temporary (reversible) process whereby cells are held in the spleen before
returning to the circulation; phagocytosis which represents the irreversible uptake of
non-viable cells by macrophages or destruction of viable cells which have been
damaged in some way; pooling which is the presence in the spleen of an increased
amount of blood. In contrast to sequestration, pooled cells are in continuous
exchange with the circulation.
Hypersplenism
Hypersplenism is a clinical syndrome of varied aetiology. It is characterized by:
a) Splenomegaly, although this may be only moderate.
b) A reduction in the number of one or more of the cellular components leading to
thrombocytopenia, neutropenia, anaemia and even pancytopenia.
c) Normal or increased production of the precursor cells in the marrow.
d) Premature release of cells into the peripheral blood, resulting in a mild
reticulocytosis with nucleated red cells and occasional immature granulocytes.
e) Decreased red cell survival.
f) Decreased platelet survival.
g) Hypervolaemia, if splenomegaly is marked.
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The central role of the spleen in producing hypersplenism is confirmed by the
finding of reversal of the abnormality in haematological counts following
splenectomy.
3.1.1.4 Pathogenesis of splenomegaly in portal hypertension:
The pathogenesis of splenomegaly in portal hypertension due to hepatic cirrhosis is
not clear. It is generally believed that passive vascular congestion due to back
pressure on the splenic circulation from the hypertensive portal vein is responsible
for enlargement of the spleen. However, this may not be the only factor determining
spleen size, as splenomegaly does not reverse totally with decompressive
portosystemic shunt surgery or with the insertion of TIPSS (Jalan et al, 1996b).
Further, there is evidence of splanchnic hyperaemia and increase in splenic arterial
blood flow with the development and progression of portal hypertension in hepatic
cirrhosis. Size of the splenic artery and blood flow, as assessed by ultrasonography
and duplex doppler scanning, correlates with the size of the spleen. However, this
could be the result of splenomegaly rather than the cause of it. There is also
evidence that lymphoid tissue hyperplasia could be a factor in producing
splenomegaly in hepatic cirrhosis. This is supported by autopsy studies in humans
(McMichael, 1934) as well as experimental data from animals with portal
hypertension where it has been shown that splenic tissue implants grow and replicate
lymphoid cells actively after implantation into the subcutaneous tissues implying the
importance of factors other than portal congestion in the production of splenomegaly
in liver disease (Dumont et al, 1974). In summary, at least three factors seem to
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participate in the production of splenomegaly, i.e., portal hypertension, increase in
splanchnic blood flow and lymphoid hyperplasia.
3.1.2 Splanchnic blood flow in portal hypertension
Normally, the portal venous system conveys about 1.0-1.5 litres of blood/min to the
liver. The normal portal venous pressure is in the range 4-6 mm Hg. In portal
hypertension, there is a reduction of hepatopetal flow to a variable degree. This is
most marked in the extra-hepatic variety of portal hypertension. Reduction of portal
vein blood flow in patients suffering from cirrhosis has been recorded as 450 + 350
mls./min (range 0-1690 mls./min) (Moreno et al, 1975).
Although, there is a general agreement, that portal blood flow is reduced in portal
hypertension, there is some disagreement about the frequency of retrograde blood
flow (centrifugal to the liver) in the portal vein. Radiological studies of the portal
circulation have certain limitations but the direct introduction of contrast material
into the portal vein shows that retrograde flow can occur, usually in patients with
large collateral vessels (Takayasu et al, 1982; Rector et al, 1988).
3.1.2.1 Portal-systemic shunts and collateral vessels
Almost all of the portal venous blood normally flows towards the liver, but in portal
hypertension a variable amount is shunted into the systemic circulation through
collateral vessels or by intra-hepatic shunts, which bypass the sinusoids and join the
hepatic veins directly. The proportion of the portal blood shunted varies and may
reach 100 percent (Lebrec et al, 1976; Okuda et al, 1977). Collateral vessels are an
important sign of raised portal pressure. They can occur at different sites. The most
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important ones, clinically are in the stomach and oesophagus, where they may bleed
(Figure 3.3). They may also occur in the rectum and anus, in the anterior abdominal
wall, around the umbilicus, behind the colon and duodenum and over the bare area
of the liver. The extent of shunting increases with time and presumably, therefore
with the progression of liver disease. Shunting is especially marked in patients who
suffer from gastro-oesophageal variceal bleeds (Groszmann et al, 1972; Lebrec et al,
1976).
The major risk factor for variceal haemorrhage seems to be the size of oesophageal
varices and it has been suggested that blood flow through the varices is a more
important risk factor than portal pressure (Sauerbruch et al, 1988). The direct
measurement of blood flow through oesophageal varices remains difficult to
achieve, but it has been proposed that blood flow in the azygos vein into which the
varices drain, reflects blood flow in the varices. Blood flow in the azygos vein in
individuals without portal hypertension is about 175 mls./min. (Bosch et al, 1985).
Factors such as propranolol, which cause a reduction in the azygos blood flow
(Lebrec et al, 1981; Bosch et al, 1984) are believed to also reduce variceal blood
flow which may be important in reducing the risk of variceal haemorrhage. Thus,
blood flow through the azygos vein reflects the degree of shunting through gastro-
oesophageal collaterals, and the azygos blood flow in patients who have bled from
varices reaches about 600 mls./min. Until direct measurement of variceal blood flow
becomes routinely possible, recording azygos blood flow remains an important tool




Figure 3.3: When the portal circulation is obstructed, collateral circulation
develops to return the portal blood into the systemic veins.
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3.1.3 Evaluation of portal hypertension and liver function in hepatic cirrhosis.
The haemodynamic alterations in the portal circulation due to hepatic cirrhosis are
complex. Various methods have been used to visualize the portal system.
Angiographic procedures can visualize the portal system very well (Burcharth,
1979) but their invasiveness and cost precludes their use for screening or follow up.
CT scanning (Ishikawa et al 1980; Waller et al, 1984) and MRI (Ohtomo et al, 1986)
can delineate intra-abdominal vessels well, but assessment of direction and velocity
of flow are difficult. On the other hand, ultrasound is a less expensive, non-invasive,
readily available and relatively accurate method of investigation (Dach et al, 1981).
3.1.3.1 Abdominal ultrasonography and doppler ultrasound
Ultrasound can visualize the portal system accurately (Dach et al, 1981; Dokmeci et
al, 1981; Juttner et al, 1982; Kane et al, 1982; Hill et al, 1985; Subramanyam et al,
1983) and doppler adds reproducible information about the presence, direction and
velocity of portal blood flow (Patriquin et al, 1987). Therefore, doppler ultrasound
has advantages over other imaging modalities to make it a good procedure for
diagnosis and follow up of portal hypertension.
Taylor (1975) noted that a large portal vein on ultrasound was a sign of portal
hypertension. Since then a number of studies have been undertaken to differentiate
normal from portal hypertensive patients on the basis of portal vein diameter
measurements (Bolondi et al, 1984; Zoli et al, 1985; Kurol and Forsberg, 1986).
Measurements should be performed in the fasting state and in the supine position
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because the splanchnic vein diameters increase significantly (Bellamy et al, 1984;
Rahim et al, 1985) after a meal and in the left lateral decubitus position.
Zoli (1985) examined 100 cirrhotics and 100 pair-matched controls and found that
the sum of the expiratory diameter of the superior mesenteric vein and the splenic
• • 2vein in excess of 9.2 mm/m body surface area was a reliable sign of portal
hypertension (sensitivity 91 percent and negative predictive value 92 percent) (Zoli
et al, 1985). However, in an angiographic study on 64 cirrhotic patients and 33
controls, Lafortune (1984) found no correlation between elevated portal pressure and
splenic vein diameter. In view of these discordant reports, the value of venous
diameter measurements as a discriminatory test for portal hypertension is still
controversial.
Another approach is to look at respiratory variations in venous diameter. In healthy
individuals, the diameter of the superior mesenteric vein and splenic vein increase
markedly during inspiration (Bolondi et al, 1984). This can be explained by
mechanical compression of the liver during inspiration, leading to a decrease in
hepatic outflow while splanchnic inflow continues, the net effect being distension of
the splanchnic veins (Rabinovici and Navot 1980). These respiratory changes are
significantly less or even absent in portal hypertensive patients.
The presence of collaterals is another highly specific sign of portal hypertension.
Although large spontaneous shunts are easily detected by sonography, small
collaterals can be difficult to resolve. This may be why the reported sensitivity for
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demonstrating collaterals ranges from 12-85 percent (Dokmeci et al, 1981; Bolondi
et al, 1984). A coronary vein diameter in excess of 5 mm is a further sign of portal
hypertension, with a reported sensitivity of 64 percent (Subramanyam et al, 1983). A
coronary vein more than 7 mm indicates severe portal hypertension with a danger of
variceal bleeding (Lafortune et al, 1984).
Studies to estimate the volume of blood flow in portal hypertension using doppler
ultrasound have been reported (Moriyasu et al, 1984; Ohnishi et al, 1985; Moriyasu
et al, 1986; Sato et al, 1987). The principle of estimating volume flow by doppler
insonation technique is simple: measure the average velocity of blood flowing in the
portal vein using the doppler method, multiply by the cross-sectional area of the
vessel, and thus obtain the flow volume. The ultrasonic duplex scanner combines
pulsed doppler with real-time imaging, thus allowing both measurements to be
made.
Although mean velocity and cross-sectional area measurements are subject to
practical and theoretical problems, the results of these studies are more or less
consistent. There is a significant decrease in mean portal blood flow velocity in
portal hypertension (Moriyasu et al, 1984; Ohnishi et al, 1985), but the total portal
flow volume often does not change and may even increase (Gill, 1985) due to a
significant increase in cross-sectional area. This observation can be quantified in a
congestive index, which is the cross-sectional area divided by the mean velocity.
This is significantly higher in patients with portal hypertension compared to normal
patients (Moriyasu et al, 1986).
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3.1.3.2 WHVP and PPG.
The normal portal pressure ranges from 4-6 mm. Hg. and the pressure gradient
between portal and hepatic veins ranges from 1-4 mm. Hg. Pressure values above
these limits define the presence of portal hypertension. The formation of
oesophageal varices requires a pressure gradient above 10 mm. Hg., and it has been
proposed that the development of ascites requires a gradient above 8 mm. Hg (Bosch
etal, 1986).
The measurement of portal pressure gives useful information in several clinical
situations. The finding of a high portal pressure will confirm the presence of portal
hypertension (Reynolds et al, 1970). Furthermore, it may be useful in the follow-up
of patients after TIPSS (Dick et al, 1995), and to measure the response to drug
therapy for the prevention of variceal haemorrhage (Bosch et al, 1993). It can also
offer useful information about the cause of portal hypertension, because a normal
WHVP is strongly suggestive of presinusoidal hypertension (Mc Cormick and
Burroughs, 1990).
Portal pressure is well correlated with the severity of cirrhosis as assessed on liver
biopsy (Krogsgard et al, 1984; Picchotti R et al, 1994) or by Child-Pugh
classification (Pugh et al, 1973). The latter is the most commonly used means for
assessing the severity of liver disease and patient survival (Table 3.1).
Although, it is generally accepted that a PPG of 12 mm. Hg. is necessary for the
occurrence of variceal haemorrhage, (Viallet et al, 1975; Garcia-Tsao et al, 1985;
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Table 3.1: Pugh's modification of Child's grading of the severity of cirrhosis
Clinical and biochemical
measurements
Score 1 point Score 2 points Score 3 points
Serum bilirubin (pmol/l)









1 -4 4-6 >6
Serum albumin (gm/1) >35 28-35 <28
Ascites none slight Moderate or
more
Encephalopathy grade none 1 and 2 3 and 4
Child's - Pugh Grade A = 5 or 6 points
Child's - Pugh Grade B = 7 to 9 points
Child's - Pugh Grade C = 10 to 15 points
Minimum score = 5 points, Maximum = 15 points
(Pugh et al, 1973)
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Lin et al, 1989; Rigau et al, 1989), the relationship between the severity of portal
hypertension and the risk of haemorrhage remains controversial.
Portalpressure measurement
Several direct and indirect techniques have been described to evaluate portal
pressure. The direct measurements are all invasive procedures involving
catheterization of the portal vein. This can be performed by percutaneous
transhepatic or intrasplenic puncture, by using a transjugular approach or by direct
puncture of a mesenteric vein at laparoscopy. Pressures in oesophageal varices have
been determined endoscopically, either by using a direct needle puncture of the varix
or by using a pressure transducer that is positioned against the wall of the varix
(Figure 3.4). Significant disadvantages of these techniques are their invasive nature
and the potential need for anaesthesia or sedative agents, which may modify the
splanchnic and systemic haemodynamics. The indirect measurement of portal
venous pressure by measuring WHVP has been shown to correlate closely with
directly measured portal pressure. The principle of the technique is that a catheter
introduced as far as it can go (usually through the right femoral or jugular vein) into
a hepatic venous radicle (i.e. wedged) reflects, the pressure at the next point of free
communication with the hepatic circulation, which is the sinusoidal portal pressure.
The wedged position is verified by the absence of reflux of injected contrast material
and pressure measurements are taken in this wedged position (WHVP). If the
catheter is now withdrawn until free blood can be obtained the catheter should be













Figure 3.4: Various techniques which can be used for the measurement of
Portal Pressure.
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FHVP. PPG is the difference between the wedged and free pressures and reflects the
gradient between portal vein and vena caval pressures.
A modification of the conventional method, the balloon catheter technique, has been
described (Novak et al, 1977; Groszmann et al, 1979). With this method, the FHVP
and the WHVP are obtained by inflating a balloon in the tip of the catheter. This
method is the most commonly used today because it has an almost 100 percent
correlation (r=0.98) with the older technique for PPG and it offers several
advantages (Groszmann et al, 1979). Firstly, inflation and deflation of the balloon is
much simpler than moving the catheter into and out of the wedged position.
Secondly, it permits repeated pressure measurements more easily. Thirdly, injections
of contrast media, which might result in a false negative increase in pressure are not
needed to confirm the wedged position.
Although it is well established that WHVP is identical to portal pressure in cirrhotic
dogs (Groszmann et al, 1979) and in alcoholic cirrhosis, such a good relationship in
non-alcoholic liver disease has not been shown (Boyer et al, 1977; Pomier-
Layrargues et al, 1985). However, two recent studies (Lin et al, 1989; Iwao et al,
1994) showed an excellent correlation between portal venous pressure and WHVP in
hepatitis B- and C-related cirrhosis and suggested that the measurement of PPG
reliably reflects the degree of portal hypertension in posthepatitic cirrhosis. Thus, the
WHVP looks to be adequate for portal pressure measurement in most patients. There
are no comparative studies in primary biliary cirrhosis, autoimmune cirrhosis or
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primary sclerosing cholangitis, which, although all have a presinusoidal component,
also have a significant sinusoidal component in the cirrhotic stage.
3.1.3.3 Radionuclides in hepatosplenic imaging.
The liver radionuclide scan is a map of the distribution of RE cells within the field
of view. These cells are found normally particularly in the liver, spleen, bone
marrow and lung. Colloid particles are removed from the circulation by
phagocytosis into the RE cells and then remain there. The rate at which colloid is
extracted from the blood is closely related to the number of RE cells in the tissue
being perfused. Since the mass of the liver in adults is normally eight to ten times
that of the spleen, the distribution of intravenously injected colloid is approximately
90 percent to the liver and 10 percent to the spleen, with a small fraction entering the
bone marrow and lungs.
RE cells are distributed uniformly within the liver and the number of colloid
particles injected is enough to produce a uniform distribution of radioactivity within
the normal liver. Heterogenous uptake (patchy) is seen with widespread small focal
lesions or diffuse parenchymal disease like cirrhosis of the liver. Splenomegaly as a
result of portal hypertension shows increased colloid uptake, whereas that which
enlarges due to infiltration usually shows normal or decreased uptake.
Colloid shift
The uptake of colloid in the liver, spleen and bone marrow depends upon their blood
flow and extraction efficiency. Even in severe liver disease there is only a modest
81
loss of extraction efficiency, so the major mechanism for reduced uptake of colloid
is altered blood flow. In diffuse liver disease both intrahepatic and extrahepatic
shunting contribute to a reduction in effective liver blood flow. Splenic blood flow is
usually increased and this together with the reduction in effective liver perfusion
leads to an increase in the proportion of colloid taken up by the spleen.
3.1.3.4 SPECT
Liver scintigraphy has achieved renewed importance following the introduction of
SPECT (Hill et al, 1980; Khan et al, 1981; Straus et al, 1982). Since SPECT
provides high contrast images, the lesion detectibility of SPECT is superior to that of
conventional imaging (Holman et al, 1979; Maublant et al, 1981; Jaszcak et al,
1982). The capability of SPECT to quantify volumes invitro has also been
demonstrated (Kan et al, 1979; Shapiro et al, 1980; Keyes et al, 1981; Tauxe et al,
1982). Several reports have appeared in which SPECT determined volumes were
compared with known phantom volumes (Shapiro et al, 1980; Tauxe et al, 1982).
Others compared SPECT estimates of liver volume with those calculated from body
weight and height (Kan et al, 1979). Accurate and reproducible results in volume
measurement have been achieved by this technology.
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3.2 STUDIES RELATING TO SPLENOMEGALY IN PORTAL
HYPERTENSION DUE TO HEPATIC CIRRHOSIS.
3.2.1 Splenomegaly; Clinical aspects
3.2.1.1 Background
Splenomegaly is an early sign of portal hypertension and is a useful pointer towards
making a diagnosis of portal hypertension in cirrhosis of the liver (Sherlock S,
1989). However, the spleen has to enlarge significantly before becoming palpable
making clinical palpability an insensitive diagnostic tool for early splenomegaly in
portal hypertension. Ultrasonography is a useful, non-invasive and widely available
technique for measuring spleen size invivo (McGaham and Goldberg, 1998) but its
role in difficult clinical situations like obesity and ascites is not clear.
Furthermore, the pathogenesis of splenomegaly in cirrhosis is multifactorial
(Dumont et al, 1974) and the relationship of spleen size to the development ofGOV
and bleeding from them and severity of liver disease has not been thoroughly
investigated (also see sections 3.1-3.1.1.4, 3.1.2, 3.1.3.1).
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3.2.1.2 Aims
The aims of the present study were to retrospectively compare the detection of
splenomegaly clinically with spleen size measured by imaging in patients suffering
from cirrhosis of the liver and also to determine the value of abdominal ultrasound
in assessing spleen size. The relationship of spleen size to the development of
bleeding GOV and severity of liver disease has also been investigated.
3.2.1.3 Patients and Methods
Case notes of 111 patients who died of liver cirrhosis, at the Royal Infirmary of
Edinburgh, Scotland, during a 10 years period (1988-1998) and underwent autopsy
were analyzed. Aetiology of liver cirrhosis, age and sex of patients, clinical
palpability of the spleen, the presence of GOV, ascites and autopsy spleen weight
were recorded. Spleen size as assessed by clinical palpation during the last
admission of the patient prior to death was noted and ultrasonically determined
length of spleen shortly before death where available was recorded. There was a
time gap of less than four weeks between clinical and ultrasound examination of
each patient. Severity of liver disease as assessed by Child's grade (Pugh et al, 1973)
was also noted. The relationship between clinical palpability, ultrasonic dimensions
and autopsy spleen weight was studied. The presence of bleeding GOV and Child's
score was also correlated with spleen size.
Statistical analysis: This was done using SPSS software. Non-parametric Mann-
Whitney 'u' test and Kruskal-Wallis test were used to compare mean spleen weight
of palpable and non-palpable spleens in the absence of ascites and mean weight of
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palpable spleens in the presence of moderate, small or no ascites respectively.
Pearson's chi-square test was used for comparison of variceal size and bleeding
episodes in patients with and without splenomegaly (Table 3.3). Independent
samples't' test was used to compare the mean spleen weight in patients with large
and moderate varices versus those with small or no varices.
3.2.1.4 Results:
The mean age of patients at death was 60.5 years (median 61 years; range 16-90
years), the male/female ratio being 68/43 patients (61.26/38.74%). Aetiology of
chronic liver disease is shown in Table 3.2. Most patients had Child's grade C
cirrhosis, being present in 57 (51.3%) as compared to 13 (11.7%) and 41 (37.0%) of
Child's grade A and B respectively. Eighty-one patients (73%) had ascites (mild 12,
moderate 34, severe 35 patients). Seventy patients (63.1%) had varices documented
at upper gastrointestinal endoscopy prior to death (large 28, moderate 26 and small
16 patients).
Splenomegaly at autopsy, which was taken as spleen weight greater than 150 gms.
was observed in 93 (83.8%) patients. Figure 3.5 shows the relationship between
clinical palpability and autopsy spleen weight in the absence of ascites, showing that
palpable spleens are bigger than impalpable spleens. Comparing spleen weights in
all patients, including those with ascites, spleens which were palpable (571.7±81.0
gms.) were twice as heavy at autopsy than those which were not palpable (281+16.2
gms. p=0.003).
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Comparison of autopsy spleen weights (mean weight[gm.] ± s.e.m) in patients
having palpable spleens in the presence of moderate and small amount and those
without ascites is shown in Figure 3.6. There was only one patient with palpable
spleen in the severe ascites group, making valid statistical analysis difficult for this
group and therefore was not included in the analysis.
Although spleen weights in Child's grade A&B vs. C were not significantly
different (375±39.7 vs.332.5± 30.6 gms. p>0.05), it was less often palpable in
Child's C patients (p=0.002). Patients who had splenomegaly at autopsy had larger
varices and a history of GOV bleeds as compared to those with normal spleen
weight (Table 3.3). Autopsy spleen weight was greater in patients who had large to
moderate sized varices at endoscopy as compared to those who had smaller varices
and had not bled from them (Table 3.4).
Abdominal ultrasonography carried out on overnight fasted patients showed that
autopsy spleen weight had a strong correlation with ultrasonically determined length
of the organ shortly before death (r=0.78, p=0.001; Figure 3.7).
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Table: 3.2 Aetiology of chronic liver disease in 111 patients with portal
hypertension.
AETIOLOGY Number = n (%)
Alcohol 64 (57.7)
Primary Biliary Cirrhosis 13 (11.7)
Cryptogenic Cirrhosis 8 (7.2)
Haemochromatosis 4(3.6)
Post Hepatitic Cirrhosis 2(1.8)
Primary Sclerosing Cholangitis 1 (0.9)
Portal Vein Thrombosis + Cirrhosis 1 (0.9)
Alpha 1 Anti-trypsin Deficiency 1 (0.9)
Idiopathic Portal Hypertension 1 (0.9)














Figure: 3.5 The comparison of spleen weight (gms.) between palpable and not
palpable spleen in the absence of ascites.
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Table 3.3 Comparison of variceal size and history ofGI bleeds between patients
with enlarged and normal sized (autopsy weight <150 gms.) spleens.
Factors Spleen (n) p-value
Enlarged Normal
Variceal size
• Large & Moderate 50 5
• Small and Absent 45 11 0.06
Bleed
• Yes 63 7
• No 31 10 0.04
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Table: 3.4 Comparison of autopsy spleen weight (gms.) between patients






















Figure 3.6: Mean weight of palpable spleens (gms) ± s.e.m. in patients with (A)
moderate ascites (B) small ascites and (C) without ascites.
p = ns
A (n=4) B (n-7) C(n=ll)
Ascites
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Figure3.7:TherelationshipofSpleelength(cm.)vs.l nw ig tg
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3.2.1.5 Discussion
In a retrospective analysis of case records of 111 patients suffering from cirrhosis of
the liver who died during a 10 years period (1988-1998) and underwent autopsy, the
correlation of autopsy spleen weight to clinical palpability, severity of liver disease
and its impact on palpability has been investigated. Clinical correlates of portal
hypertension like the development of GOV and bleeding from these vessels have
also been correlated to spleen size.
Although it is observed from the present data that spleens which were heavier at
autopsy were more often palpable in life, there was a considerable overlap of spleen
sizes in the palpable and non-palpable spleen groups (Figure 3.5), impairing the
sensitivity of palpation as a clinical tool in diagnotics. This is in agreement with the
findings of Ratnoff and Patek (1942) who analyzed autopsy data on alcoholic
cirrhotic patients and observed a considerable overlap in liver and spleen weights
between palpable and non-palpable groups.
Furthermore, the presence of ascites makes clinical palpation more difficult and the
spleen has to enlarge much more before becoming palpable in the presence of ascites
when compared to patients without ascites, and there is also a considerable overlap
of spleen weight between groups (Figure 3.6). Hence, there is a need for a laboratory
investigational tool to measure spleen size accurately.
Abdominal ultrasonography has been used for a number of years with a steady
improvement in the quality of imaging leading to better sensitivity and specificity in
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diagnosis of liver disease (Weill, 1996). We have used it in our patients to measure
maximum length of spleen and correlated it with autopsy spleen weight. The good
correlation of autopsy spleen weight and ultrasonically determined length (Figure
3.7) indicates that abdominal ultrasonography can be used to estimate spleen size
accurately, in clinical practice. Zhang and Lewis (1987) compared radio-isotopically
determined size of spleen with spleen volume determined following splenectomy
and found a good correlation. We have used spleen weight as a measure of actual
spleen size and compared it with ultrasonographically determined spleen
dimensions, which is a much simpler and non-invasive technique to determine
spleen size compared to radionuclide studies.
The pathogenesis of splenomegaly in hepatic cirrhosis is multifactorial, but
haemodynamic factors could be the most important determinants of spleen size. The
presence of larger varices and more frequent bleeds in patients with larger spleens
suggests a possible role for increasing portal pressures and splanchnic blood flow
secondary to vasodilatation in cirrhosis of liver in producing splenomegaly. The
good correlation of spleen size with portal vein blood flow volume, as shown
subsequently (Section 3, Figure 3.9), and the finding here of a relationship of
increasing spleen size with larger varices and a history of bleeds suggests the
importance of portal haemodynamic factors in producing splenomegaly. However, it
is not clear from the results of the present investigation if splenomegaly leads to
these haemodynamic changes in hepatic cirrhosis or develops as a consequence of
them. Since these complications of portal hypertension are important clinical
consequences of disease, spleen size measured non-invasively by ultrasonography
94




In conclusion, the present study highlights the problems in clinical diagnosis of
splenomegaly. Palpation of the spleen is of limited value in diagnosing early
splenomegaly and the presence of ascites further impairs palpability. Abdominal
ultrasound assesses spleen size accurately and allows splenomegaly to be identified
easily. Spleen size correlates well with the presence of larger GOV and of bleeding
from theseGOV, but no correlation with Child-Pugh's grade has been observed.
96
3.2.2 Measurement of spleen size and its clinical correlates in hepatic cirrhosis.
3.2.2.1 Background
Splenomegaly is a cardinal feature of hepatic cirrhosis complicated by portal
hypertension and is observed in a large proportion of such patients. Mechanisms
whereby it is produced continue to be debated. Attempts to assess the relationship of
spleen size to factors such as portal pressure, portal haemodynamics and features of
hypersplenism require reliable methods of measuring spleen size, like
ultrasonography, radionuclide imaging, CT scanning and MRI. Few studies have
compared these methods to one another leading to uncertainty in interpreting the
results of studies using different methods.
3.2.2.2 Aims
To compare ultrasonography with radionuclide imaging in measuring spleen size in
patients suffering from cirrhosis of the liver and portal hypertension. Spleen size has
also been related to the peripheral blood features ofhypersplenism.
Spleen volume has been compared with portal haemodynamic measurements to see
whether these might explain the splenomegaly of portal hypertension.
97
3.2.2.3 Patients and Methods
Twenty-five patients (sixteen males) with hepatic cirrhosis and portal hypertension
were studied prospectively. Ethical approval for the study was obtained from the
Lothian regional ethics committee. Cirrhosis was diagnosed by liver biopsy in seven
patients; of these seven patients, portal hypertension was diagnosed by WHVP in 3
patients and finding of GOV in 4 patients. Cirrhosis was diagnosed by clinical
features, abnormal liver function tests and ultrasonography in 18 patients; of these
patients, portal hypertension was diagnosed by WHVP measurement in 9, from the
presence ofGOV in 7, and splenomegaly in 2 patients. Fifteen patients had alcoholic
cirrhosis, 5 had primary biliary cirrhosis, 2 had autoimmune hepatitis and cirrhosis,
1 had hepatitis C virus liver disease and 2 had cryptogenic cirrhosis.
Ultrasound imaging was carried out after an overnight fast using an Acuson 128
instrument with a 3.5 MHz transducer. The abdomen was scanned initially, and the
shape, size and the texture of the liver was noted, together with the presence or
absence of ascites. The spleen was then examined to measure spleen size. The
greatest length, transverse diameter and thickness at the hilum were measured. These
were then multiplied together and a further factor of 0.6 was included to obtain an
approximation of the volume. The portal vein was examined during quiet respiration
with the patient supine and in the right anterior oblique position. The cross-sectional
area was measured immediately below the bifurcation on three occasions, and a
mean value was obtained. Mean averaged velocity was then measured using pulsed
doppler on three occasions and a mean value was calculated. An approximation of
the flow volume was then calculated by multiplying the average cross-sectional area
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(cm ), the mean time averaged velocity (cm/sec), and a factor of 60 to obtain flow
volume in ml/min.
Radionuclide imaging of liver and spleen was carried out on the same day as
ultrasonography after administration of 140 MBq of 99Tcm albumin colloid and
SPECT was performed using a GE 400 AT gamma camera and a Seimens
Microdelta Plecs Computer. Data were collected in 64 views, each 64x64 pixels,
over an arc of 360 degrees. Transverse slices were constructed by back projection
using a Butterworth filter of order 3 with a cut-off at 0.5 of the Nyquist frequency.
Liver and spleen volumes were determined by a semi-automatic method whereby the
operator viewed the transverse slices as a movie sequence, first determining which
slices contained images of the organ concerned and then drawing a rectangular ROI
that enclosed the entire organ. Each frame was then smoothed twice using a nine-
point weighted filter to reduce statistical noise, and the volume of the cuboid
described by the rectangular ROI and the selected frames were searched to
determine the maximum value. The operator was shown each frame in turn and
given the opportunity to redraw the ROI of the frame to exclude intruding structures
(e.g. liver in the spleen ROI). Then, for each frame, all pixels above a threshold of
50% of the maximum were summed. The 50% threshold was determined by
calibrating the pixel size, then imaging phantoms with volumes in the range 400-
1000 ml. at various thresholds to determine which gave the most accurate result.
Percentage uptake of the total injected dose of colloid by the liver and spleen, the
L/S ratio and uptake of radio-isotope by the spleen/unit volume of the organ was
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calculated and correlated with spleen size and severity of liver disease as assessed by
Child's score (Pugh et al, 1973).
Sample trace of hepatosplenic SPECT in one of the patients is shown in appendix V.
The WHVP and FHVP were measured at hepatic vein catheterization using a
balloon occlusion sidewinder catheter (Cordis) and the portal pressure gradient
(PPG) calculated (PPG =WHVP-FHVP) in fifteen of the twenty-five patients.
Sample trace ofFHVP and WHVP from one of the patients is shown in appendixVI.
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Measurement ofAzygos vein bloodflow
This was carried out following the insertion of an azygos catheter (Webster Lab Inc)
into the azygos vein under fluoroscopic screening in seven of the twenty-five
patients only. The electric integrity of the thermistor was checked prior to insertion
into the patient by a custom built circuit tester made by the Department of Medical
Physics, Royal Infirmary of Edinburgh, Scotland..
Estimation of azygos vein blood flow was made by the reverse thermodilution
technique (Hayes et al, 1992) using 5% dextrose at room temperature at 50 ml./min.
as injectate. The syringe pump (Harvard model 22 modified to meet BS5724
Standard) was used to deliver the dextrose accurately into the distal lumen of the
azygos catheter. The electrical connection of the catheter was connected to a
custom- built IBM model PS2-286 microcomputer interface to give real time values
for blood flow.
The haemodynamic and imaging studies were done within the same week for each
patient.
Statistical analysis: Data were analyzed using Statistical Package for Social
Scientists (SPSS software).Linear correlations between various variables were




There was a close correlation between ultrasonographically and radio-isotopically
determined spleen volume (r=0.95, p<0.001; Figure 3.8). There was a good
correlation between the spleen volume determined ultrasonically and the portal vein
blood flow volume (ml./min.) (r=0.57, p<0.008; Figure 3.9).
No significant correlation was found between spleen size, PPG, portal vein blood
flow velocity or the azygos vein blood flow. The radionuclide uptake of the spleen
increased as the volume of the spleen increased (r=0.43, p<0.04; Figure 3.10) but no
correlation was found between liver and spleen uptake of radioisotope. Spleen
volume was negatively correlated with the WBC count (r= -0.43, p=0.05; Figure
3.11), but no correlation between the spleen volume and the haemoglobin
concentration or platelet count was observed. The phagocytic activity of the spleen
as evidenced by radionuclide uptake was negatively correlated with the haemoglobin
concentration (r= -0.48, p<0.04; Figure 3.12) and WBC count (r= -0.46, p<0.04;
Figure 3.13) but no correlation was found between spleen radionuclide uptake and
platelet count.
Since multiple variables have been correlated with each other in this analysis
assessing simple linear correlations, there is a potential for a type 1 error being high
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3.2.2.5 Discussion
The present investigation has attempted to explain the cause of splenomegaly in
cirrhosis of the liver and also investigated the relationship of haematological
parameters of hypersplenism to spleen size and radionuclide uptake. The close
correlation of spleen volume as determined by ultrasonography and radionuclide
uptake in splenomegaly due to cirrhosis of the liver shows that these methods of
measuring spleen size are comparable. Zhang and Lewis (1987) compared
ultrasonography and scintigraphy in measuring spleen size in haematological
disorders. Ultrasonography measures total spleen mass by assessing volume,
whereas scintigraphy depends upon organ blood flow and functionally active
reticuloendothelial tissue to show splenic dimensions. The good comparability of
these two methods of measuring spleen size implies that the two methods can be
used alternatively. It also means that the phagocytic cell mass and blood flow in the
spleen increases as the spleen enlarges as is seen in splenomegaly of haematological
disorders. Thus, RE cell hyperplasia must be an important factor in producing
splenomegaly.
The increase of radionuclide uptake by the spleen is not related to and thereby
possibly not a consequence of diminishing liver uptake of radionuclide because there
was no correlation between liver and spleen colloid uptake on scintigraphic
measurement in our patients. This conclusion, however, is not in agreement with the
results of previous studies (Jacob et al, 1963). This difference in observation may be
accounted for by differences in the patient populations studied in the two
investigations.
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A number of factors are important in the production of Hypersplenism in cirrhosis of
the liver. Hypersplenism is defined as one or more of thrombocytopenia, leucopenia
and sometimes anaemia with enlargement of the spleen and a normal or
hypercellular bone marrow. The formed elements of blood are suppressed to varying
degrees and there is recovery after splenectomy (Tumen, 1970, see also section
3.1.1.3). Various mechanisms to account for the development of Hypersplenism in
the splenomegaly of portal hypertension in hepatic cirrhosis have been proposed
(Doan, 1949). These include increased pooling ofblood cells in the spleen, increased
destruction of blood cells in the spleen, dilutional effects of an increased blood
volume and humoral factors (Schaffner et al, 1985). Thrombocytopenia is the most
common manifestation of Hypersplenism in cirrhosis and portal hypertension and
previous studies have quoted a negative correlation between spleen size and platelet
count (Al-Khishen et al, 1985). The results of the present investigation do not show
any correlation between the platelet count and ultrasonic spleen volume or
phagocytic activity of the spleen as reflected in the radionuclide uptake scan
suggesting that other factors than spleen size and phagocytic activity must also be
important in determining the circulating platelet levels. These could include the
presence and amount of immunoglobulin on the platelet surface (Barrison et al,
1982). The results of the present study show a negative correlation of the WBC
count to spleen size measured by ultrasonography (Figure 3.11) and radionuclide
uptake of spleen (Figure 3.13). The spleen size and increased phagocytic activity of
RE cells reflected on radionuclide scan may therefore be more important in relation
to leukopenia in Hypersplenism. The haemoglobin levels were inversely related to
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the radioisotope uptake by the spleen (Figure 3.12). This suggests the importance of
RE cell activity in the spleen in determining red blood cell turnover.
Splenomegaly in cirrhosis is accompanied by important haemodynamic changes,
and splenomegaly in cirrhotic patients may in fact result from these
pathophysiological changes (Blendis et al, 1969; Merkel et al, 1985). The strong
positive correlation of the portal vein cross-sectional area and portal blood flow
volumes with spleen size points to a close relation between circulatory factors and
splenomegaly, but does not indicate which is the cause and which is effect.
Furthermore, the lack of correlation of spleen size with portal vein pressure and
collateral vein blood flow through the azygos vein implies a complex rather than a
simple relationship. One interpretation of these data might be that spleen size is
determined, at least early in the disease process by portal congestion, thereby
explaining the close association with portal vein blood flow volume. As the liver
disease progresses, however, congestion does not increase because decompression
via portal collaterals measured by azygos blood flow occurs. Indeed, porta-systemic
shunting through the azygos system increases significantly, as the liver disease
advances (Braillon et al, 1986).
It is interesting that although a number of studies have found doppler ultrasound
measurements valuable in predicting events or drug responses in patients with portal
hypertension, it is the congestive index (ratio of portal vein cross-sectional area and
velocity) rather than cross-sectional area alone that is clinically relevant, again
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suggesting the complex nature of the relationship between haemodynamic factors
and splenomegaly (Moriyasu et al, 1986).
Portal hypertension and its consequences develop slowly over years, and there is
likely to be a considerable temporal separation between the development of
established portal hypertension and the mechanisms causing splenomegaly. The
patients studied in the present investigation had well established portal hypertension,
often with oesophageal varices which are a late development in this condition, and
haemodynamic measurements at this stage may not reflect changes present during
the development of splenomegaly.
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3.2.2.6 Conclusions
In conclusion, the results point towards the general importance of circulatory factors
in splenomegaly of hepatic cirrhosis but cannot delineate primary or secondary
mechanisms. Hypersplenism in portal hypertension affects the different formed
elements of the blood to different degrees and these studies point to splenomegaly
and its reticuloendothelial effects as being more important in leucopenia and
anaemia than in thrombocytopenia where extrasplenic factors seem to be more
important.
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3.2.3 The role of SPECT in assessing liver function in hepatic cirrhosis.
3.2.3.1 Background
Splenomegaly is an early and important sign of portal hypertension due to cirrhosis
of the liver. If the spleen is not palpable and is not enlarged on imaging, the
diagnosis of portal hypertension is questionable (Sherlock S, 1989). However, the
pathogenetic mechanisms whereby splenomegaly occurs continue to be debated and
the relationship of spleen size, R-E cell phagocytic function and vascularity of the
organ to the severity of liver disease has seldom been studied (Alstead et al, 1987).
Conventional two-dimensional scintigraphy has been used in the diagnosis (Millete
et al, 1973) and evaluation of disease severity in cirrhosis of liver (Castell and
Johnson, 1966; Beckerman and Gottschalk, 1971). However, improvements in
imaging techniques have led to its replacement by other methods such as
ultrasonography (Koga and Moikawa, 1975; Niederan et al, 1983), CT scanning
(Heymsfield et al, 1979), SPECT (Straus et al, 1984; Mut et al, 1988) and MRI
(Williams et al, 1985). SPECT allows a three dimensional assessment of the liver
and spleen (Kan and Hopkins, 1979, see also section 3.1.3.4). Whereas SPECT of
the liver has been shown to give useful information about disease severity, the place
of spleen SPECT has been investigated in only a small number of patients (Alstead
et al, 1987) and its place in this regard is not clear.
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3.2.3.2 Aim
To determine the value of SPECT of spleen in assessing severity of liver disease in
hepatic cirrhosis.
3.2.3.3 Patients and Methods
99Tcm -albumin colloid was used to perform hepato-splenic SPECT in twenty-five
patients (sixteen males) suffering from cirrhosis of the liver of varied aetiology.
Cirrhosis was diagnosed on the basis of histology in seven patients. In others,
cirrhosis was diagnosed by clinical features, abnormal liver function tests and
ultrasonography.Ultrasound imaging was carried out after an overnight fast using an
Acuson 128 with a 3.5 MHz transducer. The abdomen was scanned initially and the
shape, size and texture of the liver was noted, together with the presence or absence
of ascites. The spleen was then examined to measure spleen size as an indicator of
portal hypertension. The portal vein was examined during quiet respiration with the
patient supine and in the right anterior oblique position; the cross-sectional area was
measured immediately below the bifurcation on three occasions, and a mean value
was obtained (see also section 3.2.2.3). Radionuclide imaging of liver and spleen
was carried out after administration of 140 MBq of 99Tcm albumin colloid and
SPECT was performed using a GE 400 AT gamma camera and a Seimens
Microdelta Plecs Computer (see also section 3.2.2.3).
Statistical analysis: This was done using SPSS software. ANOVA test was applied
to calculate the significance between groups of patients in Table 3.5 and simple
linear correlation done for variables in Figure 3.14.
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3.2.3.4 Results
Twenty-five patients were studied. Fifteen had alcoholic cirrhosis, 5 had primary
biliary cirrhosis, 2 had autoimmune hepatitis and cirrhosis, 1 had hepatitis C virus-
induced liver disease and 2 had cryptogenic cirrhosis.
Table 3.5 shows the relation of spleen uptake of colloid/unit volume of spleen (%
uptake of injected dose of isotope/ml) and L/S ratio to disease severity. The spleen
seems to enlarge with worsening of liver disease from Child's grade A to B, but then
fails to enlarge any further and may actually regress in size with the development of
collaterals as liver disease worsens to Child's grade C.
Although total uptake of radio-colloid (% injected dose) is not significantly different
between groups, the spleen uptake/unit volume is higher in Child's grade C patients
implying more vascularity per unit of tissue. L/S ratio diminishes with worsening
liver function which again suggests decrease in liver blood flow and also phagocytic
cell mass relative to the spleen.
Figure 3.10 shows the positive relationship of spleen uptake of colloid (% of
injected dose) to volume of spleen as assessed by radionuclide study (r=0.43,
p=0.039). Spleen uptake of colloid/unit volume showed statistically significant
negative association with ultrasonically determined volume of spleen (r=0.46,
p<0.04: Figure 3.14), implying no net increase in vascularity of the organ/unit of
tissue.
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Table: 3.5: The relation of spleen uptake of colloid/unit volume of spleen (% of




of injected dose of
isotope)
41.53 ^19.54 41.23 ± 18.09 54.15 ± 15.79 0.374
Spleen Volume
(mis)
590 ± 272 777 ±447 444 ±221 0.26
Spleen Uptake per
unit volume (% of
injected dose of
isotope/ml)
0.084+0.056 0.059 ±0.019 0.135 ±0.041 0.035
A vs B } ns
L/S ratio 1.18 ± 0.58 0.81 ±0.56 0.35 ±0.079 0.049
A vs B}ns
B vs C }ns
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3.2.3.5 Discussion
SPECT of the spleen, although not used frequently in diagnosis, is a non-invasive
and safe procedure which gives reliable results (Meek et al, 1984). The amount of
radio-pharmaceutical administered exposes the patient to a minimum dose of
radiation. Investigations relating to liver and spleen scintigraphy have mostly used
Sulphur or Tin Colloid of 99Tcm (Parkin et al, 1983; McLaren et al, 1985; Bolton, et
al, 1988; Rutland and Que, 1995). However, there are problems in the preperation of
these colloids which are overcome with albumin colloid and this exposes the
operator to a minimum of radiation dose (Saha et al, 1986). We have used 99Tcm
albumin colloid to accomplish hepato-splenic SPECT in our patients.
Although larger spleens take up more radio-colloid, this is not a reflection of
increasing vascularity per unit of tissue, as the uptake/unit volume decreases with
increasing spleen size (Figure 3.14). This suggests that splenic enlargement in portal
hypertension due to hepatic cirrhosis is not solely due to vascular congestion and
that other factors might also be important.
Radionuclide uptake/unit volume of spleen increases as liver disease gets worse
(Table 3.5), signifying increasing blood flow with worsening liver disease. This is in
agreement with the concept that splanchnic hyperaemia gets worse with worsening
liver disease.
L/S ratio is a useful parameter which reflects the ratio of liver to spleen blood flow.
As the results of the present investigation suggest a good correlation of this ratio to
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In conclusion, the present investigation has used non-invasive and safe means to
assess liver function in hepatic cirrhosis and showed a significant correlation of
grade of liver dysfunction as assessed by Child-Pugh's system with indices like L/S
uptake ratio of radioisotope and spleen uptake of colloid/unit volume of the spleen.
Splanchnic blood flow changes with worsening of liver function and increasing
spleen size have also been assessed indirectly, by this method, as the uptake of
colloid by the R-E cells is dependant upon rate of blood flow.
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SECTION 4
DIABETES MELLITUS AND HEPATIC CIRRHOSIS
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4.1 INTRODUCTION
4.1.1 Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis of
the liver.
Impairment of glucose tolerance and liver disease frequently occur simultaneously
(Megeysi et al, 1967; Petrides and DeFronzo, 1989). Over the past decades, it has
been well documented that 60-80% of cirrhotics have glucose intolerance and that
overt diabetes develops in up to 30% of these patients (Megeysi et al, 1967). The
diabetes that develops is usually mild and non-insulin dependant (NIDDM). Most
cirrhotics exhibit increased peripheral insulin levels and severe insulin resistance
(Proietto et al, 1980; Cavallo-Perin et al, 1985; Taylor et al, 1985). The impairment
of insulin action lies in the peripheral tissues (muscles) and results from a defect in
insulin-mediated glycogen synthesis (Kruszynska et al, 1988; Petrides et al, 1991).
In contrast, hepatic insulin sensitivity is well-maintained as evidenced by a normal
suppressive effect of insulin on liver glucose output at least in the early stages
(Petrides et al, 1991).
Conflicting data exists regarding the pattern of insulin secretion in liver disease.
Stimulation of insulin secretion by arginine (Greco et al, 1979), tolbutamide
(Pelkonen et al, 1981), intravenous glucose (Magnusson et al, 1987) and oral
glucose ingestion (Proietto et al, 1984) has been reported to be decreased (Greco et
al, 1979, Pelkonen et al, 1981, Magnusson et al, 1987), normal (Magnusson et al,
1987) or increased (Proietto et al, 1984). These data have been derived from
peripheral plasma insulin assays (after it has undergone dilution and the effect of
hepatic first pass metabolism) or from C-peptide concentrations (which are assumed
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to be a better index of insulin secretion). Insulin secreted from the endocrine
pancreas in cirrhosis undergoes hepatic first pass metabolism, portosystemic
shunting through collateral vessels and the effect of dilution before it is measured at
the peripheral sites. It is therefore, important to measure insulin secretion at its
origin (portal vein) before it undergoes changes, which could modify it, qualitatively
and quantitatively. Direct measurement and quantification of pattern of insulin
secretion in man has not been done previously, although data from the dog model is
available (Porksen et al, 1995b).
4.1.1.1 Methods of quantifying insulin secretion and action
The glucose clamp technique
A comprehensive understanding of the mechanism of disorders of glucose
homeostasis in man requires the assessment of multiple physiological variables.
Among the primary variables are the beta-cell response to glucose and the sensitivity
of body tissues to insulin. There have been attempts to derive these variables from
data obtained on glucose tolerance tests. In the oral version of the test, plasma
glucose concentration rises and then falls; mean glucose curves derived from large
populations are smooth, but curves on individuals are mainly erratic. Plasma insulin
concentration curves generally follow a similar but lagging time course. In order to
relate the response of the beta-cell (as assessed by changes in plasma insulin
concentration) to the ever-changing stimulus of the plasma glucose concentration,
the use of an "insulinogenic index" has been proposed and widely used (Perley et al,
1966; Seltzer et al, 1967). The index is computed from the ratio of the insulin-to-
glucose (I/G) concentrations. The same data has been used (plasma glucose and
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insulin values) to compute an index of tissue sensitivity to insulin, the glucose-to-
insulin ratio (G/I ratio). The problem in using such a ratio results from the feedback
loop relating these two variables and from the fact that neither variable is held
constant. Thus, a rise in plasma glucose concentration stimulates the beta-cell
release of insulin, the resultant rise in plasma insulin concentration stimulates the
cellular uptake of glucose, and the plasma glucose concentration falls. These
processes are, however, not sequential as described above, but occur simultaneously.
Studies of these two processes invitro are not subject to these problems. The excised
pancreas or isolated islet preparation can be perfused at fixed hyperglycaemic levels
and individual tissues can be perfused at fixed insulin concentrations. It is with this
type of control in mind that the glucose clamp technique has been developed. The
technique places the plasma glucose concentration under the investigator's control
and thus breaks the simple glucose-insulin feedback loop. Both beta-cell sensitivity
to glucose and tissue sensitivity to insulin can be quantified.
In the hyperglycaemic clamp technique, (DeFrenzo et al, 1979) the plasma glucose
concentration can be raised and maintained at a chosen hyperglycaemic
concentration within narrow limits. Because the stimulus to the beta-cell is
controlled, studies of beta-cell sensitivity among different subject populations can be
reliably compared. Furthermore, the maintenance of the same steady state plasma
glucose concentration in all subjects obviates the need for using the I/G ratio and
allows the plasma insulin response to be assessed directly. The hyperglycaemic
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clamp has a major advantage in that, unlike the OGTT, the time course of the
amount of glucose metabolized by the body can be quantified.
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4.1.2 Diabetes mellitus and TIPSS insufficiency.
TIPSS is an effective method of treating portal hypertension and its complications
(Jalan et al, 1995a). However, shunt insufficiency and occlusion are major limiting
factors in the success of this form of treatment (Latimer et al, 1998). Primary shunt
patency at six months, one year and two years has been reported as 71.2%, 58.2%
and 21.4% respectively (Stanley et al, 1996). Rates of shunt insufficiency have
however been shown to vary from 25-80% in different studies (LaBerge et al, 1993;
Martin et al, 1993; Peramau et al, 1993; Jalan et al, 1994; Lind et al, 1994; Rossle et
al, 1994). Shunt stenosis can be treated by balloon angioplasty, extension of the stent
or the insertion of a co-axial stent, but re-occlusion occurs. (Dabos et al, 1996).
The pathogenesis of shunt stenosis is not entirely clear. One of the factors
determining this is the time course of occlusion. Whilst early occlusion is associated
with thrombosis, delayed shunt dysfunction is predominantly due to pseudointimal
hyperplasia within the shunt (Henri et al, 1997). A number of factors have been
assessed as predictors of shunt insufficiency (Jalan et al, 1995b) and biliary leak into
the shunt lumen has also been implicated (Jalan et al, 1996a).
Diabetes mellitus, which is common in patients suffering from cirrhosis of liver,
(Shearman and Finlayson, 1989) leads to smooth muscle cell proliferation and
endothelial cell dysfunction in blood vessel walls. This is secondary to a number of
growth factor abnormalities, which develop in this condition. (Aronson et al, 1996).
These vascular changes could also be responsible for delayed TIPSS insufficiency
due to pseudo-intimal hyperplasia within the stent lumen.
127
4.1.2.1 Histopathology of pseudo-intima
Pseudo-intima grows over a metal meshwork stent surface, over a period of weeks to
months. The process starts off as a poorly organized fibrin and platelet clot mixed
with inflammatory and red blood cells. The covering thickens with time as collagen
fibres get more dense because the cellular component mainly consists of fibroblasts
and myofibroblasts. After about two weeks, in all stents the fibrous layer covering
the stent gets topped by a continuous layer ofmature endothelial cells. The thickness
of the pseudointima varies and in the intraparenchymal portion of the prosthesis
ranged from 200-3,500 pm with maximal values most often recorded within the
midst of the shunt (Ducoin et al, 1997).
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4.2 STUDIES RELATING TO DIABETES MELLITUS AND CIRRHOSIS:
4.2.1 Measurement of pulsatile insulin secretion in patients suffering from
hepatic cirrhosis.
4.2.1.1 Introduction
Insulin is secreted in high frequency pulses from the (3 cells of the pancreas into the
portal vein (Goodner et al, 1977). This pattern of insulin secretion has been shown to
be abnormal in subjects with Type 2 diabetes (Lang et al, 1981), their first-degree
relatives (O'Rahilly et al, 1988) and patients at risk of developing Type 1 diabetes
(Bingley et al, 1992). Diabetes mellitus that develops in hepatic cirrhosis resembles
Type 2 diabetes in its pathogenesis and manifestations and in the later stages is
accompanied by abnormalities of insulin secretion.
However, the quantification of pulsatile insulin secretion is complex. Insulin pulses
are secreted into the portal circulation and undergo significant hepatic extraction and
waveform attenuation before entering the systemic circulation (Porksen et al,
1995a). A canine model for direct portal vein catheterization has been developed to
overcome this problem (Porksen et al, 1995b). Using this model, it has been reported
that sampling from the systemic circulation results in an underestimate of both the
frequency of insulin pulses and the calculated proportion of insulin secreted in the
pulsatile mode (Porksen et al, 1995a). Studies of pulsatile secretion in humans have
been confined to the systemic circulation (Lang et al, 1979; Hansen et al, 1982;
Sonnenberg et al, 1992; O'Meara et al, 1993a; Porksen et al, 1997a, 1997b). These
studies reported a pulse frequency of 15-20 minutes (Lang et al, 1981; O'Rahilly et
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al, 1988; Bingley et al, 1992), but more recently a pulse frequency of about 6
minutes has been suggested (Porksen et al, 1997a, 1997b). It is speculated that these
differences are due to the greater sensitivity of novel insulin assays applied in the
later studies. If the true frequency of insulin pulses delivered into the portal
circulation were 6-8 minutes, it would be comparable to the frequency observed in
the isolated perfused pancreas (Stagner et al, 1985) as well as the perifused islets
(Gilon et al, 1993; Marchetti et al, 1994).
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4.2.1.2 Aims:
The present study was carried out using a previously validated deconvolution
technique for quantifying pulsatile insulin secretion to plasma insulin concentration
profiles measured simultaneously from the portal vein and the systemic circulation
in human subjects with stable and compensated cirrhosis of the liver and in situ
TIPSS .
The TIPSS catheter allowed relatively non-invasive high frequency sampling of
blood from the portal vein in conscious human subjects (Stanley et al, 1996). The
insulin secretion was quantified in the fasting basal state as well as during a
hyperglycaemic clamp study.
Using this protocol, the present study has attempted to address the following
questions. Firstly, is the frequency of pulsatile insulin secretion in man (as observed
by direct sampling from the portal vein) comparable to the frequency reported
previously from studies in isolated pancreatic islets and the isolated pancreas?
Secondly, the frequency and amplitude of secretory bursts in the portal vein has
been compared to that in the systemic circulation in order to see the impact of
hepatic extraction and dilution on the peripheral delivery of insulin. Thirdly, does
hyperglycaemia in humans (as in the dog model) enhance insulin secretion through
augmentation of the mass of insulin bursts?
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4.2.1.3 Patients and Methods
This study was approved by the Lothian ethics committee and all included subjects
provided informed written consent.
Inclusion criteria included, patients with a patent TIPSS, stable compensated
cirrhosis and normal OGTT. Exclusion criteria included decompensated liver
disease, diabetes mellitus or impaired glucose tolerance, thrombosed stent and
prolonged prothrombin time.
All patients underwent a 75 gms. OGTT 1-2 weeks prior to the study to exclude
diabetes mellitus. Of the six patients screened, one had to be excluded because of
diabetes. Patient details are presented in Tables 4.1 and 4.2.
Five patients with in situ TIPSS were studied immediately after a routine follow up
portogram to check for TIPSS patency. The patients were admitted overnight to the
Royal Infirmary of Edinburgh. After an overnight fast, a catheter inserted via the
right jugular vein was guided under fluoroscopic cover through the TIPSS into the
portal vein. The patency of the TIPSS was thus ensured. A sampling catheter was
then inserted via the right internal jugular introducer sheath into the portal vein to
allow sampling from the portal vein.
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1. 58 F 60 23 4.4
2. 61 M 71 22 5
3. 43 M 71 24 4
4. 61 M 100 33 5.8
5. 54 M 117 36 5.4
FPG = fasting plasma glucose
M= male
F= female
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4.2.1.4 Study protocol
All patients were admitted to the programmed investigation unit of the Royal
Infirmary of Edinburgh the night prior to the study and remained fasting overnight.
On the morning of the study, each subject underwent TIPSS portogram by a
radiologist and the sampling catheter was placed in the portal vein at the end of this
procedure.
A peripheral indwelling catheter for sampling purposes was also inserted in a dorsal
hand vein and the hand was warmed to 40° C by an electric blanket to enable
sampling of arterialized blood from this site. Although cirrhotic patients are already
vasodilated warming of the hand to 40° C further vasodilates the hand circulation
and makes the venous blood arterialized. An intravenous catheter was also placed in
an antecubetal vein in the contralateral arm and infused with saline at a rate of 30
ml/hour.
Once all the catheters were in place, there was a 45 min rest period prior to the
commencement of the protocol. At protocol time 0-40 min, simultaneous 1 min
sampling of arterialized blood and portal vein blood was performed to obtain the
insulin concentration profile each minute at each site in the fasting state. At protocol
time 40 min, a hyperglycaemic clamp was commenced to raise the arterialized
plasma glucose concentration to 8-9 mmol/1. This was achieved by infusion of a
variable rate glucose infusion (Dextrose 50%) controlled by a programmable
infusion pump (Harvard Infusion Pumps, Ayer, MA) connected to a personal
computer.
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Arterialized blood was sampled at 5 min intervals and the plasma glucose measured
within 2 min. Steady state hyperglycaemia was achieved by protocol time 80 min
(40 min after the clamp was begun) and the second intensive (1 min) sampling
period began.
From protocol time 80-120 min, blood was sampled at 1 min intervals from the
peripheral arterialzed line and the portal vein catheter simultaneously to determine
the insulin concentration profile during the hyperglycaemic clamp. Portal vein
sampling was completed in all five-study subjects in both the basal and
hyperglycaemic sampling periods. Arterialized sampling was completed in four
subjects only, as the peripheral sampling catheter was not working reliably.
In two subjects, portal vein blood flow volume (mls/min) was measured during the
study (pre- and post-sampling), using doppler scanning.
4.2.1.5 Assays
Plasma glucose concentrations were measured by the glucose oxidase method using
a Beckman glucose analyzer (Beckman, Palo, Alto, CA).
Plasma insulin concentrations were measured in duplicate by two-site immuno
specific insulin ELISA (Andersen et al, 1993). In brief, the assay uses two
monoclonal murine antibodies (Novo Nordisk, Bagsvaerd, Denmmark) specific for
human insulin. The detection range of this insulin ELISA was 5-600 pmol/1. At
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medium (150 pmol/1), medium-high (200 pmol/1) and high (350 pmol/1) plasma
insulin concentrations, the interassay coefficients were 3.7%, 4.0%, 4.5% and the
corresponding intra-assay variations were 2.3%, 2.1%, 2.0%. There was no cross
reactivity with proinsulin and split 32, 33 and des 31, 32 proinsulins respectively.
Plasma C-peptide concentration was assayed with a commercially available kit
(K6218; DAKO, Cambridgeshire, UK). The assay is a two-site ELISA based on two
monoclonal antibodies, using the same principles referred to above. Each sample
was assayed in duplicate; intra- and interassay variation coefficients were 2.2% and
3.3% respectively.
4.2.1.6 Data analysis
Detection and quantification ofpulsatile insulin secretion by deconvolution analysis
The plasma insulin concentration time series were analyzed by deconvolution as
previously validated (Veldhius et al, 1995) to detect and quantify insulin secretory
bursts (Porksen et al, 1995b). Deconvolution of plasma insulin concentration data
was performed with a multiparameter technique that requires the following
assumptions.
Plasma insulin concentrations measured in samples collected at 1 min intervals were
assumed to result from 3 determinable and correlated parameters:
1) a finite number of discrete insulin secretory bursts occurring at either regular or
randomly dispersed times and having:
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a) individual amplitudes (maximal rate of secretion attained within a burst) and
mass (integral of the calculated secretory event) and
b) a common half-duration (duration of an algebrically Gaussian secretory pulse
at half-maximal amplitude), which are superimposed on
c) a basal time-invariant insulin secretory rate.
2) a bi-exponential insulin disappearance model in the systemic circulation,
consisting of earlier directly estimated half lives of 2.8 and 5 min and a
fractional slow component of 0.28 in healthy fasting humans;
3) a bi-exponential insulin disappearance model in the portal circulation, consisting
of half lives of 1 and 3 min and a fractional slow component of 0.667. These
parameters achieved the statistically best fit (maximally reduced fitted variance)
of the portal-vein insulin concentration profile. All secretory rates were
expressed as mass units of insulin (picomoles) released per unit distribution
volume (litres) per unit time (min).
Statistical analysis
Data are presented as the mean ± s.e.m. Statistical comparison between groups was




The mean arterialized plasma glucose concentrations during the basal (fasting) and
stimulated (hyperglycaemic clamp) sampling periods were 5.3± 0.3 and 8.1+ 0.1
mmol/1 respectively (p<0.001). As expected, there was a rise in the mean arterialized
(basal vs. stimulated, 209+7.4 vs. 456+16.3 pmol/1, p<0.001) and mean portal vein
(basal vs. stimulated, 440+25.3 vs. 1020.7+72.3 pmol/1, p<0.001) insulin
concentration following the increase in the plasma glucose concentration from 5.3 to
8.0 mmol/1 during the hyperglycaemic clamp.
The mean arterialized C-peptide concentration also increased with hyperglycaemia
(basal vs. stimulated, 1.8+0.1 vs. 2.7+0.1 nmol/1, p<0.001) confirming an increase in
insulin secretion in response to the glucose stimulus. Throughout the study in each
subject, the portal-vein insulin concentration was higher than the corresponding
arterialized insulin concentration in both basal (p<0.001) and stimulated (p<0.001)
sampling periods (Figure 4.1).
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Figure 4.1: Mean arterialized plasma glucose (top panel) C-peptide (middle
panel) and both arterialized (open square) and portal-vein (solid squares) insulin
concentrations. T=0-40 min corresponds to the basal state, hyperglycemia was
achieved by t=80 min, when the second intensive sampling was undertaken.
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Portal vein bloodflow
The mean portal vein blood flow was measured in two cases and was 1.1 1/min and
0.8 1/min. There was no change in the portal vein blood flow between the basal state
and the hyperglycaemic clamp.
Insulin concentration profdes (Figure 4.2, 4.3)
Inspection of the plasma insulin concentration profiles from the individual patients
indicated the presence of recurrent oscillations in both arterial and portal circulations
in all patients. The magnitude of these oscillations was much larger in the portal
circulation (Figure 4.2) in both the basal and stimulated states compared with the
corresponding profiles from the systemic circulation. The amplitude of the
oscillations increased during hyperglycaemia (Figure 4.2). The range of the insulin
pulse amplitude observed in the portal circulation was 100-1000 pmol/1 in the basal
state and increased to 200-3000 pmol/1 during the hyperglycaemic clamp. This
contrasts with the corresponding range of pulse amplitudes observed in the systemic
circulation of 10-30 pmol/1 in the basal state and 40-100 pmol/1 in the stimulated
state (Figure 4.3).
Pulse detection
When the insulin concentration profiles were subjected to deconvolution, insulin
pulses were invariably identified in both the portal and systemic circulation (Figure
4.4a & b, 4.5a & b). The pulse mass increased in response to hyperglycaemia in both
portal (basal vs. stimulated, 418±155 vs. 1078±368 pmol/1, p<0.05) and systemic





























Figure 4.2. Plasma insulin concentration profiles from the basal (t=0-40 min)
and hyperglycemic clamp (t=80-120 min) period in case 1 and 2 obtained
from the arterialized (open squares) and portal-vein (solid squares) sampling
sites. Note that the scales are adjusted in the left and right panels to
accommodate the insulin concentration range observed. In all cases,
oscillations in insulin concentrations are much greater in the portal-vein than




Figure 4.3: Plasma insulin concentration profile observed from the
arterialized sampling catheter in case 2 in the basal state (t=0-40 min)
and during hyperglycemia (t=80-120 min). Note that the scale has been
adjusted for each sampling period to maximize the visualization of
oscillations. In comparison with the arterialized insulin concentration
profiles in Figure 4.2, the expanded scale clearly illustrates the
prominent oscillations in insulin concentration in the both basal and
stimulated state.
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Figure 4.4a: The portal-vein insulin concentration profile and
corresponding deconvolved insulin secretion rates obtained during the
intensive sampling periods in the basal state (left panels) and during the




























Figure 4.4b: The arterialized insulin concentration profile and corresponding
deconvolved insulin secretion rates obtained during the intensive sampling
periods in the basal state (left panels) and during the hyperglycemic clamp periods
(right panels) for case 1.
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Figure 4.5a: The portal-vein concentration profile and corresponding
deconvolved insulin secretion rates obtained during the intensive sampling
periods in the basal state (left panels) and during the hyperglycemic clamp






















Figure 4.5b: The arterialized insulin concentration profile and corresponding
deconvolved insulin secretion rates obtained during the intensive sampling period
in the basal state (left panels) and during the hyperglycemic clamp periods (right







































Figure 4.6: The mean insulin inter-pulse interval (top panel), pulse mass (middle
panel) and pulse amplitude (bottom panel) during the basal sampling period and
stimulated hyperglycemic period evaluated by sampling from the portal-vein
(open panels) versus the arterial catheter (shaded panels). Units are minutes
(pulse interval), pmol/1 (mass), and pmol/l/min (amplitude).
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Furthermore, the measured pulse mass/ volume of distribution was about 5 fold
greater in the portal circulation in both the basal and stimulated states. The pulse
amplitude determined by deconvolution was also markedly larger (7-8 fold) in the
portal circulation in both basal (portal vs. systemic, 254±158 vs. 23±2.7 pmol/l/min)
and stimulated (portal vs. systemic, 524±337 vs. 12+2.1 pmol/l/min) states
confirming the impression gained by inspection of the insulin concentration profiles.
The inter-pulse interval (Figure 4.6) determined by direct portal-vein sampling was
similar (p>0.05) in both the basal sampling period as well as during the clamp
(Figure 4.6). The pulse interval detected by sampling from the systemic circulation
was slightly but not significantly higher than that observed in the portal circulation.
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4.2.1.8 Discussion
The present study uses direct and high frequency sampling from the portal vein to
confirm that insulin is secreted in humans almost exclusively in discrete secretory
bursts and that hyperglycaemia enhances insulin secretion by selective amplification
of the mass of insulin contained within each secretary burst. Furthermore, we could
establish that the prehepatic frequency of insulin pulses is about 5 min, which in fact
corresponds with that observed in the portal vein of dogs in vivo (Porksen et al,
1995) and from the isolated perfused islets invitro (Gilon et al, 1993; Marchetti et al,
1994).
There has been some disagreement in the literature as to the frequency of pulsatile
insulin secretion in vivo with the estimates ranging from once every 6 min. (Porksen
et al, 1995a, 1995b) to once every 20 min. (Lang et al, 1979, 1981; O'Rahilly et al,
1988; Bingley et al, 1992; Sonnenberg et al, 1992). When pulsatile insulin secretion
was measured directly from the portal vein in the dog, the interpulse interval
averaged 6 min, based on conventional insulin immunoassay and a deconvolution
analysis, which had been previously validated for insulin pulse detection (Porksen et
al, 1995a, 1995b). Although the pulse frequency corresponded to that observed in
perfused single islets invitro, it was three times greater than that observed previously
in humans by sampling from the systemic circulation (Lang et al, 1979, 1981;
O'Rahilly et al, 1988; Bingley et al, 1992; Sonnenberg et al, 1992). It was postulated
that this large discrepancy was due to the relative loss of insulin pulses in the
systemic circulation as compared to the portal circulation (Porksen et al, 1995b).
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At least in the dog model, it has been confirmed that the sampling site is important
when a conventional insulin assay is employed (Porksen et al, 1995a) since
simultaneous estimates in the portal and systemic circulations revealed different
interpulse intervals (Porksen et al, 1995a). The disadvantages of sampling from the
systemic circulation were especially evident when the only available insulin assays
were conventional immunoassays (O'Meara et al, 1993b). Even multiple replicates
by these assays, which have cross reactivity with proinsulin and insulin split
products, do not allow for fully reliable detection of high frequency insulin pulses in
the systemic circulation. However, the introduction of the more sensitive and
specific ELISA assays for insulin (Andersen et al, 1993) should theoretically
overcome some of the problems. Recently, using an ELISA for insulin
measurements, an insulin pulse frequency of ~ 8 min. has been reported when
sampling from the systemic circulation in humans (Porksen et al, 1997a). The
present study now confirms directly that the systemic sampling route can provide an
accurate estimate of insulin pulse frequency invivo circulation in humans when the
insulin concentration is measured by a sensitive and specific ELISA method and
submitted to appropriate deconvolution based analysis.
Sampling directly from the portal circulation revealed a remarkable magnitude of
insulin oscillations at this site. In the present study, the amplitude of insulin
concentration in the portal vein was 100-1000 pmol/ 1 in the basal state and
increased to 500-5000 pmol/1 during hyperglycaemia. These values in the human are
comparable to those observed in the canine portal vein (Porksen et al, 1995a, 1995b)
and presumably reflect the insulin concentration wave front to which the liver is
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exposed. The present study subjects were suffering from cirrhosis of the liver
complicated by portal hypertension requiring treatment. Subjects with stable
cirrhosis who were clinically well and had normal pre-study OGTT's were selected.
However, portasystemic shunting of blood through TIPSS and liver damage due to
cirrhosis of the liver may have resulted in less hepatic extraction of insulin. The
present study presents a model, which can be used to study insulin secretion in
cirrhotic patients in varying degrees of liver failure and glycaemic control.
Although some studies have reported that pulsatile insulin delivery to the peripheral
circulation enhances insulin sensitivity, none has yet recapitulated the magnitude of
insulin oscillations to which we observe the liver is exposed invivo during
stimulation-enhanced insulin secretion (Matthews et al, 1983; Paolisso et al, 1990).
The question remains, therefore, what the physiologic importance is, if any, of
exposing the liver to such dramatic oscillations of insulin concentration. Since the
pulsatility of peripheral insulin pulses is attenuated in patients with Type 2 diabetes
(Laedtke et al, 2000), it is likely that the liver in these patients is exposed to even
more attenuated oscillations in insulin pulse amplitude, which may contribute to the
hepatic insulin resistance characteristic of this disease (De Fronzo et al, 1982).
The remarkable transhepatic attenuation of the insulin pulse signal from the portal
circulation to the systemic circulation observed here is comparable to that observed
previously in the dog (Porksen et al, 1995a). Although the attenuation may reflect up
to 4-fold dilution of portal venous blood by the systemic venous drainage, the
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insulin pulse amplitude is damped to a much greater extent than this (~ 10 folds).
Presumably the latter reflects hepatic insulin clearance of insulin pulses.
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4.2.1.9 Conclusions
In summary, direct sampling from the portal vein in humans establishes an insulin
interpulse interval of ~ 5 min, and thereby resolves the discrepant insulin pulse
frequency reported in cirrhotic humans with TIPSS insitu. A comparable insulin
interpulse interval can also be detected by high frequency peripheral sampling with
the use of highly sensitive assay and appropriately validated pulse detection. Direct
portal vein sampling also reveals that in humans the majority of insulin is secreted in
insulin bursts, and the apparently preferential hepatic extraction of pulses lead to
post -hepatic delivery of insulin in smaller bursts. Finally, we confirm that the liver
in humans is exposed to dramatic insulin concentration oscillations that far exceed
the magnitude evaluated to date in clinical studies of insulin action invivo.
This study of insulin secretion, in human subjects has been carried out in patients
suffering from cirrhosis of the liver and portal hypertension but it seems that liver
damage and portasystemic shunting has not significantly influenced the peripheral
delivery of insulin.
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4.2.2 Role of Diabetes Mellitus in TIPSS insufficiency.
4.2.2.1 Background
TIPSS is an effective method of treating portal hypertension and its complications
(Jalan et al, 1995a). However, shunt insufficiency and occlusion are major limiting
factors in the success of this form of treatment (Latimer et al, 1998). Primary shunt
patency at six months, one year and two years has been reported as 71.2%, 58.2%




To assess the role of diabetes mellitus in producing TIPSS insufficiency.
4.2.2.3 Patients and Methods
The cohort of patients (n=248) who underwent TIPSS insertion between July 1991
and July 1997 was reviewed, looking for shunt dysfunction post-TIPSS and its
relation to diabetes mellitus.
Patients were included in the analysis if TIPSS insertion was successful, at least one
portographic shunt assessment was completed post-insertion, blood sugar profile
was available for a diagnosis of diabetes mellitus to be made and early TIPSS
insufficiency (within 1 month post-TIPSS) was absent. Patients were not entered
into the analysis if they had incomplete data, portographic follow-up was not
available, and early TIPSS insufficiency or HCC was present.
One hundred and seventy seven patients (71.4%) had successful TIPSS placement
and had blood sugar profiles available for a diagnosis of diabetes mellitus to be
made or excluded. Fifty-nine patients were excluded because of either early death,
early shunt insufficiency, or referral for porto-systemic shunt surgery or liver
transplantation within the first month following TIPSS insertion. The clinical data of
the 118 patients who were entered into the final analysis comparing diabetic vs non-
diabetic patients are presented in Table 4.1. TIPSS insertion was undertaken
according to the method described elsewhere (Jalan et al, 1994). The procedure was
carried out under sedation and analgesia with local anaesthesia, unless general
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anaesthesia was indicated because of the clinical condition of the patient. Patients
were followed up by doppler ultrasound at day seven post shunt placement to
exclude early thrombosis. Regular follow up by portography was undertaken at six
monthly intervals unless shunt occlusion was clinically suspected, which led to
earlier portographic shunt assessment.
Data were censored when the patient died, had documented shunt insufficiency, had
liver transplantation or portographic surveillance was discontinued.
Appendix VII shows gross morphology of an occluded shunt opened up after OLT.
Histology of pseudointimal hyperplasia within an occluded TIPSS is shown in
appendix VIII. Radiological appearance of pseudointimal hyperplasia as seen at
check portography is shown in appendix IX,X and XI.
Definitions
PSI was defined as the increase in PPG to >12 mm Hg (Jalan et al, 1997). However,
TIPSS is often inserted for the treatment of ascites, where the PPG may be <12 mm
Hg at the time of stent placement. In such situations, SI was defined as an increase
in PPG of 20% or more over the immediate post-TIPSS PPG (Jalan et al, 1994;
Stanley et al, 1996).
PSI was further classified into early (<1 month post shunt placement) and delayed
(>1 month post shunt placement). Diabetes was either diagnosed on OGTT or on the
basis of two random blood glucose levels >11 mmol/1 taken six months apart
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(W.H.O. criteria). Rebleeding was defined as overt haematemesis and/or melaena or
a drop of haemoglobin of greater than 2 g/dl without any other demonstrable source
of blood loss or haemolysis. Endoscopy confirmed gastroesophageal variceal bleed
or portal hypertensive gastropathy.
Statistical Analysis
The statistical analysis was carried out using the Statistical Package for Social
Scientists (SPSS) software. In order to compare risk factors for shunt insufficiency
in the diabetic and non-diabetic patients, univariate testing was first carried out. T-
tests were used to compare mean age, pre-shunt PPG and post-shunt PPG, in the two
groups of patients. Non-parametric Mann-Whitney tests were performed to compare
length of follow-up and shunt-diameter in the two groups, and chi-square tests were
performed to test for associations between presence of diabetes, gender, Child's
class, primary delayed insufficiency and variceal haemorrhage.
In order to determine which factors were independently associated with primary
delayed insufficiency, logistic regression modeling was carried out. Several clinical
and biological variables were considered for inclusion in the model including age,
gender, Child's class, shunt diameter, pre and post shunt PPG and whether the
patient had diabetes. Kaplan-Meier survival analysis was used to compare time to
delayed shunt insufficiency and a log rank test was applied to check for statistical
significance of the difference.
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4.2.2.4 Results
Diabetes was present in 28 out of 177 (15.8%) patients who had both a successful
TIPSS and blood sugar profiles. Of the 118 patients who met inclusion criteria, 23
(19.5%) patients were diabetic and 95 (80.5%) non-diabetic. Statistical testing
provided no evidence that the diabetic and non-diabetic patients differed in age, sex,
pre-shunt PPG, post-shunt PPG and length of follow up (Table 4.3). However, the
presence of diabetes was found to be associated with a better Child's class (p=0.01);
diabetic patients were more likely to have a Child's class A or B (87.0%) than non-
diabetics (56.8%). The median inserted shunt diameters were equal in the two
groups, but the inter-quartile ranges showed diabetics to have larger shunts in place
(p=0.02).
A comparison of clinical and demographic features between the study sample and
the entire TIPSS treated population is presented in Table 4.7 and confirms the true
representative nature of the sample in comparison to the TIPSS patient population
from which it is derived.
The frequency of delayed PSI in diabetic versus non-diabetic patients is presented in
Table 4.4. Diabetic patients were more likely to suffer from primary delayed
insufficiency (87.0%) than non-diabetic patients (60.0%). This is unlikely to be due
to a difference in Child's classes amongst the two groups as the incidence of shunt
insufficiency is similar in Child's classes A & B compared with C (Table 4.5). There
was no evidence of an association between the presence of diabetes and variceal
haemorrhage post shunt insertion. Cumulative shunt patency is presented in Figure
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4.7, which shows significantly reduced patency rates over time in diabetic patents
with cirrhosis of the liver (p=0.04).
Table 4.6 presents odds ratios (ORs) and 95% confidence intervals (CIs) for the
factors included in the final logistic regression model. These factors are statistically
significant when included in the model, and are independently associated with
delayed shunt insufficiency. Females are more likely than males, and diabetics are
more likely than non-diabetics, to experience shunt insufficiency (OR = 3.44, 95%
C.I. = 1.37 to 8.61, OR = 7.30, 95% C.I. = 1.87 to 28.43 respectively). However,
individuals aged 55 years or over are less likely than those in the younger age group
to experience shunt insufficiency (OR = 0.40, 95% C.I. = 0.17 to 0.94).
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Follow up period (months)
Figure 4.7: Cumulative rate of primary delayed shunt insufficiency compared
in diabetic (dotted line) versus non-diabetic (solid line) cirrhotics p=0.04.
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4.2.2.5 Discussion
This study included a large cohort of patients with TIPSS who underwent long-term
portographic follow-up. Diabetes has been shown to be associated with increased
prevalence of stent occlusion following coronary balloon angioplasty and stent
implantation (Galan et al, 1986; Reinsing et al, 1993; Weintraub, 1993). If restenosis
is viewed as an intraluminal growth process after vascular injury, similar mechanism
might be operative in TIPSS occlusion as in coronary stent occlusion. Although
there are haemodynamic differences between the high-pressure arterial circulation in
the heart and the low-pressure portal venous circulation, the turbulent flow in the
TIPSS, especially at the hepatic venous end of the stent makes it liable to injury
from stress of the jet stream of blood. This is followed by the process of repair and
endothelial regeneration and under certain circumstances may result in
pseudointimal hyperplasia and shunt insufficiency (also see section 4.1.2.1).
In our study population, the diabetic and non-diabetic groups were comparable in
their clinical characteristics except for Child's class and stent diameter. Child's class
was better and stents used larger in the diabetic group. It is a bit surprising that the
overall prevalence of diabetes was relatively low in Child's 'C' patients studied but
this may be a reflection of low numbers in the cohort. Child's class, however, was
not associated with increased prevalence of delayed PSI (Table 4.5) and larger
diameter stents in diabetic cirrhotics should have made them less liable to occlude.
Furthermore, all factors in Table 4.3 were considered for inclusion in the logistic
regression model and Child's class and shunt diameter were not independent risk
factors.
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Table 4.7 very clearly demonstrates that although the study sample is only 118
(47%) of the entire TIPSS treated group, it is still comparable to and representative
of the latter in its clinical and demographic features. The number of patients who
underwent placement of TIPSS as an emergency and those with Child's grades A&B
were proportionately slightly greater in the study sample as compared to that in the
entire TIPSS treated population, but that did not achieve statistical significance
(p>0.05). Although different complications of portal hypertension from liver
diseases of varied aetiology led to treatment with TIPSS, the most commonly treated
entity at the Royal Infirmary, where this research was carried out is oesophageal
varices due to alcoholic cirrhosis.
The lack of evidence of an association between variceal haemorrhage post shunt
occlusion and the presence of diabetes is surprising but may be due to the close
follow up in our patients, which allowed early intervention. Some of the patients
also underwent endoscopic band ligation after TIPSS, which would reduce the risk
ofbleeding.
On post-TIPSS follow-up, hepatic encephalopathy developed for the first time in
4/23 (17.4%) diabetic cirrhotics (Table 4.4) and needed standard therapeutic
measures to be instituted. Although this was a higher incidence than in the non-
diabetic patients, it was not statistically significant. The precipitation of
encephalopathy did not follow episodes of gastro-intestinal bleeding and 2 patients
each had Child's grades B & C respectively.
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This is the first study looking at the role of diabetes mellitus in occlusion and
insufficiency of TIPSS. The results of the present investigation indicate that the
presence of diabetes is associated with delayed shunt insufficiency, independently of
age and gender. Further work needs to be carried out to determine if this may be a
possible causal effect. Hyperglycaemia induces alterations of growth factor secretion
(Aronson et al, 1996), which may be important in the genesis of shunt narrowing
due to fibrous tissue and endothelial overgrowth. The role of factors such as Insulin
growth factor-1 (IGF-1), Tumour growth factor-beta (TGF-beta) and endothelins
(which have increased expression and secretory rates in individuals with diabetes
and hyperglycaemia (Taqkahashi et al, 1990; Meyer-Schwickerath et al, 1993;
Yamamoto et al, 1993)) in smooth muscle cell replication and pseudo-intimal
hyperplasia in the shunt lumen should be investigated.
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4.2.2.6 Conclusion
From a practical standpoint, the results of this study would suggest that patients
should be screened for diabetes at shunt implantation and a meticulous glycaemic
control maintained post TIPSS to try to prevent hyperglycaemia, and therefore
hopefully, minimize delayed shunt insufficiency.
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Table 4.3. Comparison of clinical data and shunt characteristics in diabetic






Age in years (mean + SD) 57.3 ±11.2 52.2 ± 12.5 0.07
Gender (Males/Females) 18/5 57/38 0.15
Child's Class (A+B/C) 20/3 54/41 0.01
Follow up in months (median; IQR) 15.0, 22.0 17.2, 18.2 0.43
Pre- shunt PPG mmHg (mean ± SD) 19.6 ±5.5 19.2 ±7.0 0.79
Post-shunt PPG mmHg (mean ± SD) 8.5 ±4.0 6.8 ±4.6 0.11
Stent Diameter in mm (median;
lower Quartile, upper quartile) 12.0; 12.0,14.0 12.0; 10.0,12.0 0.02
Stent Diameter in mm (mean±s.e.m) 12.2 ±0.32 11.44 ±0.16 0.04
SD=Standard Deviation
IQR = Interquartile Range
s.e.m = standard error ofmean
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Diabetic Non-Diabetic p value
(n=23) (n=95)




Table 4.5: Primary delayed shunt insufficiency and variceal haemorrhage in
relation to Child's class of liver disease.
Outcome Child's Class A+B Child's Class C p value
(n=71) (n=47)
Primary Delayed
insufficiency 52 (70.3%) 26(56.8%) 0.16
Variceal Haemorrhage 11(15.1%) 5(11.6%) 0.78
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Table 4.6: Final logistic regression model of primary delayed shunt
insufficiency.
Factor Number of Odds ratio p value








Less than 55 years 61








Table 4.7: Comparison of clinical data and shunt characteristics of the
study sample vs. the whole group of TIPSS treated patients.
Factor Study sample Total TIPSS treated
(n=118) patients (n=248)
Age in vears





Oesophageal varices 75 155
Gastric varices 19 40
Ascites 16 36
PHG 3 6
Oesophageal+Rectal varices 3 8
Hydrothorax 2 3
Aetiologv of liver disease
Alcoholic cirrhosis 81 161
Cryptogenic cirrhosis 5 21
PBC 10 19
Post hepatitic cirrhosis 12 20










* Independent samples t-test and chi-square test was applied to test for association
between the two groups and p value was found to be not significant in comparing
different factors (p>0.05).
SD=standard deviation
PHG= Portal Hypertensive Gastropathy
PBC= Primary Biliary Cirrhosis
PSC= Primary Sclerosing Cholangitis
CAH= Chronic Active Hepatitis
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EPILOGUE
The thesis has investigated the role of iNOS in modulating a-adrenoreceptor
mediated vasoconstriction in the normal as well as cirrhotic hepatic arteries. There
was no difference in the strength and sensitivity of contraction of the hepatic arteries
obtained from cirrhotic compared to normal individuals, studied exvivo. This could
partly be explained on the basis of the difference in time duration, which the donor
(normal) and recipient (cirrhotic) blood vessels remained exvivo following transplant
surgery and also the difference in storage media used for the two types of blood
vessels. However, this should not be a significant factor affecting contractility.
These experiments have therefore demonstrated clearly that neither a-adrenoceptor
mediated (PE) nor a-adrenoceptor independent (KC1) vasoconstriction were
impaired in hepatic arteries isolated from patients with advanced cirrhosis. This
indicates that impaired excitation-contraction coupling in the muscle cells of hepatic
arteries in cirrhotic individuals is not responsible for the impaired pressor response
associated with this condition, invivo. Furthermore, inhibition of iNOS by
incubation of the blood vessels with L-NNA made no significant difference to the
contractility of the vessels indicating that the release of vasodilators from the
vascular smooth muscle cell in arteries denuded of endothelium is not responsible
for the impaired pressor response associated with this condition. Our results,
therefore imply that an endothelium dependent factor is the important mediator of
impaired vascular tone in cirrhosis.
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Portal hypertension due to hepatic cirrhosis is also associated with a number of
complications such as splenomegaly, hepatic encephalopathy, development ofGOV
and bleeding from them, ascites and metabolic complications like diabetes mellitus.
Splenomegaly is an important early sign of portal hypertension due to hepatic
cirrhosis. In cirrhosis of the liver it signifies not only the presence of portal
hypertension, but it is also associated with potentially important sequelae like
hypersplenism. Our results have shown a definite correlation between spleen size,
the size of GOV and bleeding from varices. This might be useful, clinically in
monitoring the progression of disease.
We have studied two methods of measuring spleen size (ultrasonography and
radionuclide). We also compared the spleen size as judged by these methods with
actual spleen size as measured at autopsy. We have found that the spleen size
measured by these two methods correlates well and also correlates well with direct
measurement of spleen weight. This is an important observation in that it shows that
a non-invasive method like ultrasonography can be used to assess spleen size
accurately and indirectly monitor the size ofGOV with disease progression.
Radionuclides in diagnostic imaging in hepato-biliary disease has largely been
replaced by ultrasonography, MRI and CT scanning. However, the last two are
expensive, not readily available and CT scanning exposes the patient to a large dose
of radiation. Radionuclide uptake studies from our experiments have not only given
useful information about the structure of the spleen but also help quantitate liver
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function. A good correlation of spleen uptake of colloid/unit volume and L/S uptake
ratio of colloid with liver function has been observed. Accordingly, radionuclides
can still be used in clinical practice, where available, to assess liver function in
chronic liver disease.
Another frequently observed and important complication of hepatic cirrhosis is
diabetes mellitus. The pattern of insulin secretion in the portal vein of cirrhotic
patients has been studied using TIPSS inserted patients as a model. This has not
been studied before in human subjects and could be used in different categories of
chronic liver disease to study the pattern of insulin secretion and its relation to the
development of diabetes.
The impact of diabetes mellitus on TIPSS insufficiency has been studied. Diabetes
mellitus has been found to be a significant independent factor, in the production of
pseudointimal hyperplasia in TIPSS. This has practical implications in that Diabetes
mellitus should be sought early in patients undergoing TIPSS and treated to try to
reduce the risk of TIPSS occlusion.
In conclusion, this work has shed light on several aspects of cirrhosis and portal
hypertension and helped elucidate many facets of complications of the disease,
which may have clinical significance. This should help in understanding better, the
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Wedged hepatic venous pressure trace
Appendix VI: Free and Wedged Hepatic Venous pressure trace
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Appendix VII: Gross morphology of TIPSS, opened up after surgical removal
of cirrhotic liver at OLT. It shows metal mesh with numerous blood clots with
fibrin deposits.
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Appendix VIII: Histology of pseudo-intimal growth over TIPSS as shown on
H&E staining. It comprises of endothelium and underlying supporting tissue.
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Appendix IX: Radiograhic appearance of minimal pseudointimal hyperplasia
at check portography.
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Appendix X: Radiographic appearance of gross pseudointimal hyperplasia at
portography.
208
Appendix XI: Radiographic appearance of pseudointimal hyperplasia in a
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Aims: Splenomegaly is common in portal hypertension
due to hepatic cirrhosis, but there are little data com¬
paring different methods of spleen measurement. We
have compared ultrasound with radionuclide imaging in
measuring splenomegaly. The relation of splenomegaly
to hypersplenism and portal hemodynamic factors was
also studied. Results: Ultrasound and radionuclide mea¬
sures of spleen volume gave comparable results (r =
0.95, p < 0.0001). Phagocytic activity of the spleen mea¬
sured by radionuclide uptake increased as the volume of
the spleen increased (r = 0.46, p < 0.03) but was not
related to diminishing liver phagocytic activity. Spleen
volume was correlated negatively with leukocyte counts
(r = 0.43, p < 0.05) but not with hemoglobin or platelet
counts. Spleen radionuclide uptake was negatively cor¬
related with hemoglobin (r = 0.48, p < 0.04) and leuko¬
cyte counts (r = 0.46, p < 0.04) but not with platelet
counts. Spleen volume was related to portal vein cross-
sectional area (r = 0.91, p < 0.0001) and portal vein
blood flow volume (r — 0.57, p < 0.008) but not to portal
vein blood flow velocity, portal pressure gradient, or
azygos blood flow. Conclusions: Spleen size measured by
ultrasonography and radionuclide studies gives compa¬
rable results. Spleen phagocytic activity in cirrhosis in¬
creases as the spleen enlarges but not in relation to
decreased hepatic phagocytic activity. Spleen phagocytic
activity probably contributes to anemia and leukopenia
in the splenomegaly of cirrhosis, but other factors must
contribute to thrombocytopenia. Portal hemodynamics
are probably important in the splenomegaly, but the
interrelation is complex.
INTRODUCTION
Splenomegaly and hypersplenism are common in portal
hypertension due to cirrhosis, but the mechanisms whereby
they occur continue to be debated. Attempts to analyze the
relation of spleen size to factors such as portal pressure, portal
Received May 23, 1996; accepted Aug. 14, 1996.
hemodynamics, and hypersplenism require reliable methods of
measuring spleen size. Methods used include abdominal radi¬
ography (1), ultrasonography (2, 3), radionuclide imaging (4-
6), computed tomography (7), and magnetic resonance imag¬
ing. Few studies have investigated the comparability of these
various methods (8), leading to uncertainty in relating studies
using different methods to one another. Accordingly, we have
compared ultrasound, which measures spleen volume, with
radionuclide imaging, which measures uptake of colloid by the
reticuloendothelial cells of the spleen, in measuring spleno¬
megaly in patients with cirrhosis of liver and portal hyperten¬
sion. We have also related the results to peripheral blood
features of hypersplenism. Attempts to analyze the relation of
spleen size to such factors as portal pressures and portal he¬
modynamics have seldom been done and relatively few pa¬
tients have been studied (9-11). We have compared spleen
volume with portal hemodynamic measurements to see
whether these might explain the splenomegaly of portal hyper¬
tension.
PATIENTS AND METHODS
Twenty-five patients (sixteen males) with hepatic cirrho¬
sis and portal hypertension were studied. Cirrhosis was
diagnosed by liver biopsy in seven patients; of these seven
patients, portal hypertension was diagnosed by wedged he¬
patic venous pressure measurement (WHVP) in three pa¬
tients and by finding esophageal varices in four patients.
Cirrhosis was diagnosed by clinical features, abnormal liver
function tests, and ultrasonography in 18 patients: of these
patients, portal hypertension was diagnosed by WHVP mea¬
surement in 9, from the presence of esophageal varices in 7,
and splenomegaly in 2 patients. Of the 15 patients with
alcoholic cirrhosis, 5 had primary biliary cirrhosis, 2 had
autoimmune hepatitis and cirrhosis, 1 had hepatitis C virus
liver disease, and 2 had cryptogenic cirrhosis.
Ultrasound imaging was carried out after an overnight
fast using an Acuson 128 with a 3.5 MHz transducer. The
abdomen was scanned initially and the shape, size, and
texture of the liver was noted, together with the presence or
absence of portosystemic collaterals and ascites. The spleen
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Spleen volume on ultrasonography (mis.)
Fig. 1. Relation of spleen volume measured by ultrasonography to spleen volume measured by radionuclide imaging (scintigraphy).
was then examined. The greatest length, transverse diame¬
ter, and thickness at the hiluin were measured. These were
then multiplied together and a further factor of 0.6 was
included to obtain an approximation of the volume. The
portal vein was examined during quiet respiration with the
patient supine and in the right anterior oblique position. The
cross-sectional area was measured immediately below the
bifurcation on three occasions and a mean value obtained.
Mean averaged velocity was then measured using pulsed
Doppler on three occasions, and a mean value was calcu¬
lated. An approximation of the flow volume was then cal¬
culated by multiplying the average cross-sectional area
(mm2), the mean time averaged velocity (cm/sec), and a
factor of 60 to obtain flow volume in ml/min.
Radionuclide imaging of liver and spleen was carried out
after administration of 140 MBq of Tc 99m albumin colloid
and single photon emission computed tomography (SPECT)
was performed using a GE 400 AT gamma camera and a
Siemens Microdelta Plecs Computer. Data were collected in 64
views, each 64 X 64 pixels; over an arc of 360 degrees.
Transverse slices were constructed by back projection using a
Butterworth filter of order 3 with a cut-off at 0.5 of the Nyquist
frequency. Liver and spleen volumes were determined by a
semi-automatic method whereby the operator viewed the trans¬
verse slices as a movie sequence, first determining which slices
contained images of the organ concerned and then drawing a
rectangular region of interest (ROI) that enclosed the entire
organ. Each frame was then smoothed twice using a nine-point
weighted filter to reduce statistical noise, and the volume of the
cuboid described by the rectangular ROI and the selected
frames were searched to determine the maximum value. The
operator was shown each frame in turn and given the oppor¬
tunity to redraw the ROI of the frame to exclude intruding
structures (eg, liver in the spleen ROI). Then, for each frame,
all pixels above a threshold of 50% of the maximum were
summed. The 50% threshold was determined by calibrating the
pixel size, then imaging phantoms with volumes in the range
400-1000 ml at various thresholds to determine which gave
the most accurate result.
The WHVP and free hepatic vein pressure (FHVP) were
measured at hepatic vein catheterization using a balloon
occlusion sidewinder catheter (Cordis), and the portal pres-
c
sure gradient (PPG) calculated (PPG = FHVP - WHVP).
The azygos blood flow was measured by azygos vein cath¬
eterization using a reverse thermodilution catheter (Webster
Laboratories) with real-time display using a dedicated com¬
puter as previously described (12).
RESULTS
There was a close correlation between ultrasonically and
isotopically determined spleen volume (Fig. 1) (r = 0.95,
p < 0.001). There was a good correlation between the
spleen volume determined ultrasonically and portal vein
cross-sectional area (r = 0.91, p < 0.0001) and portal vein
blood flow volume (ml/min) (r = 0.57, p < 0.008) (Fig. 2,
3). No significant correlation was found among spleen size,
the portal pressure gradient, the portal vein blood flow
velocity, or the azygos blood flow. The radionuclide uptake
of the spleen increased as the volume of the spleen increased
(r = 0.46, p < 0.03), and there was no correlation between
liver and spleen radionuclide uptake. Spleen volume was
negatively correlated with the white blood cell count (r =
0.43, p < 0.05), but no correlation with hemoglobin or
platelet count was observed. The phagocytic activity of the
spleen as evidenced by radionuclide uptake was negatively
correlated with hemoglobin (r = 0.48, p < 0.04) and white
cell count (r = 0.46, p < 0.04), but no correlation was found
between spleen radionuclide uptake and platelet count.
DISCUSSION
Splenomegaly is a cardinal feature of hepatic cirrhosis
complicated by portal hypertension (13). The prevalence of
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Fig. 2. Relation of spleen volume measured by ultrasonography to portal
vein cross-sectional area, r = 0.91; p < 0.0001.
PORTAL VEIN PLOW VOLUME (ml/sec)
Fig. 3. Relation of spleen volume measured by ultrasonography to portal
vein flow volume, r = 0.57; p < 0.008.
splenomegaly in cirrhosis varies from 36-92% (14). The
cause of splenomegaly in cirrhosis and portal hypertension
is not well understood, but may include reticuloendothelial
hyperplasia and the hemodynamic changes associated with
portal hypertension. Several methods have been used to
visualize the spleen in vivo, and these include abdominal
radiography (1), ultrasonography (2, 3), computed tomog¬
raphy (7), and radionuclide uptake methods (4-6). Few
studies, however, have addressed the comparability of these
methods of measuring spleen size (8). The close correlation
of spleen volume as determined by ultrasonography and
radionuclide studies in our patients with splenomegaly due
to cirrhosis of liver suggests that studies using these meth¬
ods are comparable, and perhaps other methods are also
comparable. This finding is in agreement with findings of
Zhang and Lewis (15) who compared methods of measuring
spleen size in hematological disorders.
A number of factors could be important in the production
of hypersplenism in splenomegaly. Hypersplenism can be
regarded as the association of one or more of anemia,
leukopenia, and thrombocytopenia with splenomegaly, and
a normal or hypercellular bone marrow. The formed ele¬
ments of blood are suppressed to varying degrees with a
recovery after splenectomy (16). Various mechanisms to
account for the development of hypersplenism in the spleno¬
megaly of portal hypertension in cirrhosis have been pro¬
posed (17). These include increased pooling of blood cells
in the spleen, increased destruction of blood cells in the
spleen, the dilutional effects of an increased blood volume,
and of humoral factors (18). Thrombocytopenia is the most
common manifestation of hypersplenism in cirrhosis and
portal hypertension, and previous studies have reported a
negative correlation between the platelet count and spleen
size (19). We, however, could not find any correlation
between the platelet count and ultrasonic spleen volume or
the phagocytic activity of the spleen as reflected in the
radionuclide scan suggesting that other factors must also be
important. These could include the presence and amount of
immunoglobulin on the platelet surface (20). Our results
showed a negative correlation of the white cell count to
spleen size measured by ultrasonography and radionuclide
imaging, and spleen size may therefore be more important in
relation to leukopenia in hypersplenism. The increased re¬
ticuloendothelial phagocyte activity noted on radionuclide
imaging may well be important in relation to the white blood
cells. The hemoglobin was inversely related to the radionu¬
clide ultrasonography. Phagocytosis may therefore be more
important in relation to red blood cells.
Ultrasonography measures total spleen mass by assessing
volume, whereas scintigraphy depends upon functionally
active reticuloendothelial tissue to show splenic dimensions.
We found good comparability of these two methods of
measuring spleen size; this finding means that phagocytic
cell mass in the enlarged spleen increases proportionately to
its total volume as is seen in the splenomegaly of hemato¬
logical disorders (15). Thus, reticuloendothelial cell hyper¬
plasia might be important in producing splenomegaly. The
increase of phagocytic activity is not a consequence of
diminishing liver phagocytic activity because there was no
correlation between liver and spleen colloid uptake on scin¬
tigraphic measurement in our patients. This conclusion is
not in agreement with the results of previous studies (21).
Splenomegaly in cirrhosis is accompanied by important
portal hemodynamic changes. Splenomegaly in cirrhotic
patients may in fact result from these pathophysiological
changes (22, 23). The strong positive correlation of portal
vein cross-sectional area and portal blood flow volumes
with spleen size emphasizes the importance of circulatory
factors in splenomegaly, but does not indicate whether this
is a cause or a result of splenomegaly. Furthermore, the lack
of correlation of spleen size with portal vein pressures and
collateral blood flow through the azygos vein implies a
complex relationship. One interpretation of these hemody¬
namic data is that spleen size is determined, at least early in
the disease process, by portal congestion, thereby explaining
the close association with portal vein diameter. As liver
disease progresses, congestion does not increase because
decompression via portal collaterals, measured by azygos
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flow iccurs. Indeed, portasystemic shunting through the
azygo system increases as liver disease advances (24). The
lack if correlation with portal pressure may reflect individ¬
ual diferences in compliance of the portal vascular bed and
portas'stemic shunting to changes in portal pressure. It is
intere.ting that although a number of studies have found
Dopper ultrasound measurements valuable in predicting
event or drug responses in patients with portal hyperten¬
sion, t is the congestion index (ratio of portal vein cross-
sectioial area and velocity) rather than portal vein cross-
sectioiai area alone that is clinically relevant, emphasizing
again he complex nature of the relationship (25).
Thene may be a temporal separation between the devel-
opmen of established portal pressure and the mechanisms
causitg splenomegaly. Our patients had established portal
hyperension, often with esophageal varices, which are a
later envelopment in the condition, and hemodynamic mea-
surermnts at this stage may not reflect changes present
during he development of splenomegaly. In conclusion, our
results point generally to the importance of circulatory fac¬
tors ir splenomegaly but cannot delineate precise mecha¬
nisms.
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ABSTRACT
Insulin is secreted in a high frequency pulsatile manner. These
pulses are delivered directly into the portal vein and then undergo
extraction and dilution before delivery into the systemic circulation.
The reported frequency of these insulin pulses estimated in periph¬
eral blood varies from an interpulse interval of 4-20 min. We pos¬
tulated that this discrepancy is due to the attenuation of the pulse
signal in the systemic circulation vs. the portal circulation. Li the
present study we measured pulsatile insulin release directly in the
portal circulation ofhuman subjects who had indwelling transjugular
intrahepatic portosystemic stent shunts (TIPSS) to decompress por¬
tal hypertension. We quantitated pulsatile insulin secretion in both
the overnight fasted state (fasting) and during a hyperglycemic clamp
(8 mmoL/L). Direct portal vein sampling established that pulsatile
insulin secretion in humans has an interval (periodicity) of approx¬
imately 5 min. The amplitude (and mass) of the insulin concentration
oscillations observed in the portal vein was approximately 5-fold
greater than that observed in the arterialized vein and was similar to
that observed in the dog. Increased insulin release during hypergly¬
cemia was achieved through amplification of the insulin pulse mass.
In conclusion, direct portal vein sampling in humans revealed that the
interpulse interval of insulin pulses in humans is about 5 min, and
this frequency is also observed when sampling from the systemic
circulation using a highly specific insulin assay and 1-min sampling,
but is about 4-fold greater than the frequency observed at this site
using single site RIAs. We confirm that enhanced insulin release in
response to hyperglycemia is achieved by amplification of these high
frequency pulses. (J Clin Endocrinol Metab 85: 4491-4499, 2000)
INSULIN IS SECRETED in high frequency pulses (1). Thispattern of insulin secretion has been shown to be abnor¬
mal in subjects with type 2 diabetes (2) and their first degree
relatives (3) and in patients at risk of developing type 1
diabetes (4). However, quantification of pulsatile insulin se¬
cretion is complex. Insulin pulses are secreted into the portal
circulation and undergo significant hepatic extraction and
waveform damping before entering the systemic circulation
(5). We previously developed a canine model of direct portal
vein catheterization to overcome this problem (6) and re¬
ported that sampling from the systemic circulation resulted
in an underestimate of both the frequency of insulin pulses
as well as the calculated proportion of insulin released in the
pulsatile mode (5). Inevitably, studies of pulsatile secretion
in humans have been confined to the systemic circulation
(2-4, 7-12). Initially such studies reported a pulse frequency
of 15-20 min (2-4, 7, 8), but more recently a pulse frequency
of about 6 min has been suggested (11, 12). We have spec¬
ulated that these differences may reflect the greater sensi¬
tivity of novel insulin assays applied in the latter studies, and
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that the true frequency of insulin pulses delivered into the
portal circulation in humans may be 6-8 min. The latter
would be comparable to the frequency observed in the iso¬
lated perfused pancreas (13) as well as the perifused islets
(14, 15).
In the current study we applied a validated deconvolution
technique for quantifying pulsatile insulin secretion to
plasma insulin concentration profiles obtained simulta¬
neously from the portal vein and the systemic circulation in
human subjects with stable compensated hepatic cirrhosis
and an in situ transjugular intrahepatic portasystemic stent
shunt (TIPSS) (16). The TIPSS catheter allowed relatively
noninvasive high frequency sampling of blood from the por¬
tal vein in conscious human subjects. Pulsatile insulin se¬
cretion was quantified in the fasting basal state as well as
during a hyperglycemic clamp study.
Using this protocol we sought to address the following
questions. First, is the frequency of pulsatile insulin secretion
in humans (observed by direct sampling from the portal
circulation) comparable to the frequency reported previously
from studies in isolated islets, the isolated pancreas, and in
vivo by sampling from the portal vein in dogs (interpulse
interval, —6-8 min or —15-20 min as reported in some stud¬
ies using the systemic sampling site in humans). Second,
does hyperglycemia in the human (as in the dog) enhance
insulin secretion through the specific mechanism of aug¬
menting the mass of insulin bursts? Finally, we examined
whether the amplitude of the insulin concentration wave-
front to which the liver is exposed in humans approaches that
observed in the portal vein of dogs (5, 6).
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Subjects and Methods
Study subjects and design (Table 1)
This study was approved by the Lothian ethics committee (institu¬
tional review board equivalent), and all volunteers provided informed
written consent. Inclusion criteria were patientswith a patent TIPSS and
known stable compensated liver disease. Patients were deliberately se¬
lected to represent those inwhich the predominant liver-related problem
was cirrhosis and portal vein hypertension treated with a TIPSS, rather
than progressive liver failure or active hepatic inflammation. Exclusion
criteria include decompensated liver dysfunction, diabetes mellitus, a
thrombosed stent, and/or a prolonged prothrombin time. All patients
were studied 1-2 weeks before the TLPSS study and had a 75-g oral
glucose tolerance test performed to exclude diabetes mellitus. Of six
subjects screened, one was excluded from the study because of diabetes.
Five patients with in situ TIPSS were studied immediately after a
routine follow-up assessment of the patency of their TIPSS. For this
purpose patients were admitted overnight into the Royal Infirmary of
Edinburgh. After an overnight fast a catheter was placed in the right
jugular vein, and under ultrasound guidance it was passed through the
TIPSS into the portal circulation. The purpose of the clinical assessment
was to ensure that the TIPSS remained patent. Once this had been
confirmed, a catheter was inserted via the right internal jugular intro¬
ducer sheath into the portal vein to allow the present study to be
completed.
Study protocol
All study subjects were admitted to the University of Edinburgh
Wellcome Trust Clinical Research Facility at the Royal Infirmary of
Edinburgh the night before the study and remained fasting overnight.
On the morning of the study, each subject underwent TIPSS portogram
performed by a radiologist as part of the routine follow-up assessment
of the patency of the in situ TIPSS, and the sampling catheter was placed
in the portal vein at the end of this procedure.
A peripheral indwelling sampling catheter was also inserted into a
dorsal hand vein and the hand waswarmed to 40 C by an electric blanket
to permit subsequent sampling of arterialized blood. An iv catheter was
also placed in an antecubital vein in the contralateral arm and infused
with saline at 30 mL/h. Once all of the catheters were in place there was
a 45-min rest period before commencement of the protocol at approx¬
imately 1000 h. At protocol time 0-40min, simultaneous intensive 1-min
sampling of arterialized blood and portal vein blood was performed to
obtain the minutely insulin concentration profile at each site in the
fasting state. At protocol time 40 min, a hyperglycemic clamp was
commenced with the object of raising the arterialized plasma glucose
concentration to 8-9 mmol/L. This was achieved by infusion of a vari¬
able rate glucose infusion (50% dextrose) administered by a program¬
mable infusion pump (Harvard Infusion Pumps, Ayer, MA) on-line to
a personal computer. Arterialized blood was sampled at 5-min intervals,
and plasma glucose was measured within 2 min. Steady state hyper¬
glycemia was achieved by protocol time 80 min (40 min after the clamp
was begun), and then the second sampling period began. From protocol
time 80-120 min, blood was sampled at 1-min intervals from the arte¬
rialized peripheral vein catheter and the portal vein catheter to deter¬
mine the insulin concentration profile during the hyperglycemic clamp.
Portal vein sampling was completed in all five study subjects in both the
basal and hyperglycemic sampling periods. Arterialized sampling was
completed in four of the five subjects; the peripheral sampling catheter










1 58 F 60 23 4.4
2 61 M 71 22 5
3 43 M 71 24 4
4 61 M 100 33 5.8
5 54 M 117 36 5.4
FPG, Fasting plasma glucose; M, male; F, female; BMI, body mass
index.
was unreliable in the remaining subject. In two subjects portal vein blood
flow was measured during the study by use of Doppler scanning.
Assays
Plasma glucose concentrations weremeasured by the glucose oxidase
method using a glucose analyzer (Beckman Coulter, Inc., Palo Alto, CA).
Plasma insulin concentrations were measured in duplicate by two-
site immunospecific insulin enzyme-linked immunosorbent assay
(ELISA), as previously described (11, 17). In brief, the assay uses two
monoclonal murine antibodies (Novo Nordisk, Bagsvaerd, Denmark)
specific for human insulin. The detection range of this insulin ELISA was
5-600 pmol/L. At medium (150 pmol/L), medium-high (200 pmol/L),
and high (350 pmol/L) plasma insulin concentrations, the interassay
coefficients of variation were 3.7%, 4.0%, and 4.5%, and the correspond¬
ing intraassay variations were 2.3%, 2.1%, and 2.0%. There was no
cross-reactivity with proinsulin or split 32,33 and des-31,32 proinsulins,
respectively.
The plasma C peptide concentration was assayed with a commer¬
cially available kit (K6218, DAKO Corp., Cambridgeshire, UK). The
assay is a two-site ELISA based on twomonoclonal antibodies, using the
principles referred to above. Each sample was assayed in duplicate;
intra- and interassay coefficients of variation were 2.2% and 3.3%,
respectively.
Data analysis: detection and quantification ofpulsatile
insulin secretion by deconvolution analysis
The plasma insulin concentration-time series were analyzed by de-
convolution as previously validated (18) to detect and quantify insulin
secretory bursts (6). Deconvolution ofplasma insulin concentration data
Time (min)
Fig. 1. Mean arterialized plasma glucose (top panel), C peptide (mid¬
dle panel), and both arterialized (□) and portal vein (■) insulin con¬
centrations. The time 0-40 min corresponds to the basal intensive
sampling period. The hyperglycemic clamp was initiated at 40 min,
and steady state hyperglycemia was achieved by 80 min, when the
second intensive sampling period was undertaken.
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Fig. 2. Plasma insulin concentration profiles from the basal (0—40 min) and hyperglycemic clamp (80—120 min) periods in four cases obtained
from the arterialized (□) and portal vein (■) sampling sites. Note that the scales are adjusted in the left and right panels to accommodate the
insulin concentration range observed. In all cases, oscillations in insulin concentrations are much greater in the portal vein than in the
arterialized sampling site.
was performed with a multiparameter technique that requires the fol¬
lowing assumptions. Plasma insulin concentrations measured in sam¬
ples collected at 1-min intervals were assumed to result from five de¬
terminable and correlated parameters: 1) a finite number of discrete
insulin secretory bursts occurring at either regular or randomly dis¬
persed times and having a) individual amplitudes (maximal rate of
secretion attained within a burst) and mass (integral of the calculated
secretory event) and b) a common half-duration (duration of an alge¬
braically Gaussian secretory pulse at half-maximal amplitude), which
are superimposed on c) a basal time-invariant insulin secretory rate; 2)
a biexponential insulin disappearancemodel in the systemic circulation,
consisting of earlier directly estimated half-lives of 2.8 and 5.0 min and
a fractional slow component of 0.28 in healthy fasting humans; and 3)
a biexponential insulin disappearance model in the portal circulation,
consisting of half-fives of 1.0 and 3.0min and a fraction slow component
of 0.667. These parameters achieved the statistically best fit (maximally
reduced fitted variance) of the portal vein insulin concentration profile.
All secretory rates were expressed as mass units of insulin (picomoles)
released per unit distribution volume (liters) per unit time (minutes). As
the volume of distribution of insulin is unknown in the ported sampling
site in humans and undoubtedly differs from that in the systemic cir¬
culation, insulin secretion rates obtained at these two sampling sites
cannot be directly compared.
Statistical analysis
Data are presented as the mean ± sem. Statistical comparison be¬
tween groups was made using Student's two-tailed t test. To examine
the relationship between insulin concentration fluctuations observed in
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Fig. 3. Plasma insulin concentration profile observed from the arte¬
rialized sampling catheter in case 2 in the basal state (0-40 min) and
during hyperglycemia (80-120 min). Note that the scale has been
adjusted for each sampling period to maximize the visualization of
oscillations. In comparison with the arterialized insulin concentration
profiles in Fig. 2, the expanded scale clearly illustrates the prominent
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Fig. 4. A, The portal vein insulin concentration profile and corresponding deconvolved insulin secretion rates obtained during the intensive
sampling periods in the basal state (left panels) and during the hyperglycemic clamp periods (rightpanels) for case 1. B, The arterialized insulin
concentration profile and corresponding deconvolved insulin secretion rates obtained during the intensive sampling periods in the basal state
(left panels) and during the hyperglycemic clamp periods (right panels) for case 1. Note that the insulin secretion rate is (mass units per volume
of distribution)/time units. As the volume of distribution is unknown in the portal vein, these secretion units cannot be directly compared with
those obtained from peripheral sampling.
formed (19). Cross-correlation analysis relates each portal vein insulin
concentration to a corresponding value in the matching arterial series.
This procedure consists of linear correlations carried out repeatedly at
various time lags between the paired concentrations. Thus, at zero time
lag, each portal vein plasma insulin concentration is compared with a
time delayed measure (e.g. lag time minus 2 min) in the systemic cir¬
culation sample. By this means, an array of correlations can be collected
that depend on the time matching of the two series.
To examine the relationship between pulses identified in the portal
vein and systemic circulation we also performed peak concordance on
these pulses from both sites. Peak concordance is a statistically inde¬
pendent (from cross-correlation) method to establish the relationship
between detected pulses in two sampling sites. After identifying discrete
insulin secretory bursts in the two time series (portal and peripheral),
exact coincidence was defined by simultaneous pulse concordance (i.e.
peak maxima occurred within one half-sampling interval of each other).
Lagged coincidence was defined accordingly [e.g. with portal (+lags) or
peripheral (-lags] peaks occurring first. The hypergeometric probability
density (joint binomial distribution) was used to estimate the expected
number of randomly concordant pulses, and the probability of falsely
refuting the null hypothesis of pure chance concordance of the observed
coincidences.
Results
Mean plasma glucose, insulin, and C peptide concentrations
(Fig. 1)
The mean arterialized plasma glucose concentrations dur¬
ing the basal (fasting) and stimulated (hyperglycemic clamp)
sampling periods were 5.3 ± 0.3 and 8.1 ± 0.1 mmol/L,
respectively (P < 0.001). As expected, there was a rise in the
mean arterialized (basal vs. stimulated, 209 ± 7.4 vs. 456 ±
16.8 pmol/L, p < 0.001) and mean portal vein (basal vs.
stimulated, 440 ± 25.3 vs. 1020.7 ± 72.3 pmol/L; P < 0.001)
insulin concentration after the increase in the plasma glucose
concentration from 5.3 to 8 mmol/L during the hypergly¬
cemic clamp. The mean arterialized C peptide concentration
also increased with hyperglycemia (basal vs. stimulated,
1.8 ± 0.1 vs. 2.7 ± 0.1 nmol/L; P < 0.001), confirming an
increase in insulin secretion in response to the glucose stim¬
ulus. Throughout the study in each subject, the portal vein
insulin concentration was higher than the corresponding
arterialized insulin concentration in both basal (P < 0.001)
and stimulated (P < 0.001) sampling periods (Fig. 1).
Portal vein blood flow
The mean portal vein blood flow values in the two cases
in which it was measured were 1.1 and 0.8 L/min. There was
no change in the portal vein blood flow between the basal
state and the hyperglycemic clamp.
Insulin concentration profiles (Figs. 2 and 3)
Inspection of the plasma insulin concentration profiles
from the individual patients indicated the presence of re-
\
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TABLE 2. Liver function studies
Type of Alk phos GGT Bilirubin Albumin ALT INR
cirrhosis (40-125 U/L) (5-35 u/L) (2-17 /xmol/L) (36-47 g/L) (10-40 ixL) (2-4.5)
Alcoholic 125 124 56 32 14 1.4
Alcoholic 80 20 17 43 27 1
Alcoholic 146 100 42 34 56 1.3
Alcoholic 135 61 147 35 35 1.7
Alcoholic 92 54 17 41 33 1.2
ALT, Alanine amino transferase; Alk Phos, alkaline phosphatase; GGT, y-glutamyl trasferase; INR, international normalized ratio.
Normal ranges in parentheses.
Panel A.










































Fig. 5. A, The portal vein concentration profile and corresponding deconvolved insulin secretion rates obtained during the intensive sampling
periods in the basal state (left panels) and during the hyperglycemic clamp periods (right panels) for case 2. B, The arterialized insulin
concentration profile and corresponding deconvolved insulin secretion rates obtained during the intensive sampling periods in the basal state
(left panels) and during the hyperglycemic clamp periods (right panels) for case 2.
current oscillations in both arterial and portal circulations in
all patients. The magnitude of these oscillations was much
larger in the portal circulation (Fig. 2) in both the basal and
stimulated states compared with the corresponding profiles
from the systemic circulation. The amplitude of the oscilla¬
tions increased during hyperglycemia (Fig. 2). The range of
the insulin pulse amplitude observed in the portal circulation
was 100-1000 pmol/L in the basal state and increased to
200-3000 pmol/L during the hyperglycemic clamp. This con¬
trasts with the corresponding range of pulse amplitudes
observed in the systemic circulation of 10-30 and 40-100
pmol/L in the basal and stimulated states, respectively (Fig. 3).
Pulse detection
When the insulin concentration profiles were subjected to
deconvolution, insulin pulses were invariably identified in
both the portal and systemic circulation (Figs. 4 and 5). The
pulse mass increased in response to hyperglycemia in both
portal (basal vs. stimulated, 418 ± 155 vs. 1078 ± 368 pmol/L;
P < 0.05) and systemic (basal vs. stimulated, 75 ± 10 vs. 241 ±
61 pmol/L; P < 0.05) circulations (Fig. 6). Furthermore, the
measured pulse mass/volume of distribution was about
5-fold larger in the portal circulation in both basal and stim¬
ulated states. The pulse amplitude determined by deconvo¬
lution was also markedly (7- to 8-fold) larger in the portal
circulation in both basal (portal vs. systemic, 254 ± 158 vs.
23 ± 2.7 pmol/L-min) and stimulated (portal zjs. systemic,
524 ± 337 vs. 71 ± 19.8 pmol/L-min) states, confirming the
impression gained by inspection of the insulin concentration
profiles. The corresponding four pulse half-duration esti¬
mates were similar, with a global mean of 2.9 min. The
interpulse interval (Fig. 6) determined by direct portal vein
sampling was similar in the basal sampling period and dur¬
ing the clamp (Fig. 6). The pulse interval detected by sam-
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Fig. 6. The mean insulin interpulse interval (top panel), pulse mass
Cmiddle panel), and pulse amplitude (bottom panel) during the basal
sampling period and the stimulated hyperglycemic period evaluated
by sampling from the portal vein (openpanels) vs. the arterial catheter
(shaded panels). Units are minutes (pulse interval), picomoles per L
(mass), and picomoles per L/min (amplitude).
pling from the systemic circulation was slightly, but not
significantly, higher than that observed in the portal
circulation.
In the portal circulation, the calculated proportion of in¬
sulin derived from discrete insulin secretory bursts was 64 ±
1.6% in the basal state and 93 ± 2.9% during the hypergly¬
cemic clamp. In contrast, in sampling from the systemic
circulation, the calculated proportion of insulin secreted in
the pulsatile mode was apparently lower than that from the
simultaneous sample measurements obtained from the por¬
tal circulation (basal state, portal vs. systemic, 66 ± 1.8% vs.
35 ± 4.1%; P < 0.05) and stimulated (portal vs. systemic, 93 ±
2.9% vs. 56 ± 1.2%; P < 0.01). Both autocorrelation and peak
concordant analysis independently revealed a relationship
between insulin oscillations in the portal vein and the sys¬
temic circulation (Figs. 7 and 8).
Discussion
The present study uses direct and high frequency sam¬
pling from the portal vein to affirm that insulin is secreted in
humans in discrete secretory bursts, and that hyperglycemia
enhances insulin secretion by selective amplification of the
mass of insulin contained within each secretory burst. Fur¬
thermore, we could establish that the prehepatic frequency
of insulin pulses is approximately 5 min, which, in fact,
corresponds to that observed in the portal vein of dogs in vivo
(5, 6) and from isolated perfused islets in vitro (14, 15).
Our conclusion that most insulin secreted into the portal
circulation is derived from pulses is contingent upon the
assumptions required for the deconvolution method em¬
ployed (see Materials and Methods). It should also be noted
that the half-life for insulin used in these studies for portal
vein insulin concentration deconvolution was obtained by a
best-fit approach to the portal vein insulin concentration
profiles. Directmeasurement of the volume of distribution or
half-life at this site by a bolus injection upstream of the HPSS
sampling catheter in a mesenteric vein is not practicable in
conscious humans. Nonetheless, similar studies in dogs with
surgically implanted catheters arrived at the same conclusion
that most insulin is secreted in discrete insulin bursts (6).
Also, a prior study in humans sampling from the systemic
circulation came to the same conclusion (11).
There has been some disagreement in the literature about
the frequency of pulsatile insulin secretion in vivo, with es¬
timates ranging from about 6 (5,6) to about 20 (2-4,7,8) min.
Whenwemeasured pulsatile insulin release directly from the
canine portal vein, the interpulse interval averaged 6 min,
based on a conventional insulin immunoassay and a decon¬
volution program specifically validated for insulin pulse de¬
tection (5, 6). Although this pulse frequency corresponded to
that observed in perfusion of single islets in vitro, it was 3
times greater than that observed previously in humans by
sampling from the systemic circulation (2-4, 7, 8). We pos¬
tulated that the reason for this large discrepancy was the
relative loss of insulin signal when insulin pulses are exam¬
ined in the systemic compared with the portal circulation (6).
At least in the canine model, we confirmed that the sam¬
pling site was crucial when a conventional insulin assay was
employed (5), as simultaneous estimates in the portal vein
and the systemic circulation revealed insulin interpulse in¬
tervals of 6.7 and 9 min, respectively (5). The insulin pulse
detection was further obscured by using a 2-min sampling
regimen in the systemic circulation, as employed in some
previous reports (7). The disadvantages of sampling from the
systemic circulation were especially evident when the only
available insulin assays were conventional immunoassays
(20). Even multiple replicates by these assays, which have
cross-reactivity with proinsulin and insulin split products,
do not allow for fully reliable detection of high frequency
insulin pulses in the systemic circulation. However, the in¬
troduction of the more sensitive and specific ELISA assays
for insulin (17) should theoretically overcome some of these
problems. Recently, using an ELISA for insulin measure¬
ments, we reported an insulin pulse frequency of approxi¬
mately 8 min when sampling in the systemic circulation in
humans (11, 12). The present study now confirms directly
that the systemic sampling route can provide an accurate
estimate of insulin pulse frequency in vivo in humans when
the insulin concentration is measured by a sensitive and
specific ELISA method and submitted to appropriate decon-
volution-based analysis.
Sampling directly from the portal circulation revealed a
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Basal Arterial vs Ba^al Portal
Fig. 7. Cross-correlation analysis of
arterial and portal vein insulin concen¬
tration data in the basal and stimulated
states. These data illustrate that
changes in serial portal vein insulin
concentrations precede those in the sys¬
temic circulation by 1-3 min (P < 0.05
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remarkable magnitude of insulin oscillations at this site. In
the present study the amplitude of insulin concentrations in
the portal vein was about 200-1000 pmol/L in the basal state
and increased to about 500-5000 pmol/L during hypergly¬
cemia. These values in the human are comparable with those
observed in the canine portal vein (5, 6) and presumably
reflect the insulin concentration wavefront to which the liver
is exposed. Although the present study subjects were nec¬
essarily only those with portal hypertension requiring treat¬
ment, we selected subjects with normal or near-normal liver
function tests who were clinically well and had normal pre-
study OGTTs. Moreover, the range of insulin oscillations
observed in the portal vein in these subjects is comparable to
that previously observed in healthy dogs (5,6), and the portal
vein blood flow, when available, was in the normal reported
range for humans. Although some studies have reported that
pulsatile insulin delivery (to the peripheral circulation) en¬
hances insulin sensitivity, none has yet recapitulated the
magnitude of insulin oscillations to which the liver is ex¬
posed in vivo during stimulated enhanced insulin secretion
(21, 22). The question remains, therefore, what the physio¬
logical importance is, if any, of exposing the liver to such
dramatic oscillations of insulin concentration. As the mag¬
nitude of peripheral insulin pulses is decreased in patients
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Lag Interval (min, range)
Fig. 8. Peak concordance analysis of pulses detected in the portal
vein and systemic circulation. Observed number of coincident insulin
secretory bursts detected by simultaneous sampling in the portal and
peripheral circulation. The x-axis gives the lag interval between the
individually identified portal and peripheral insulin pulses. A lag
interval of(-2, -1) denotes that pulses occurred centered within this
absolute time lag (i.e. the pulses in the portal blood followed those of
insulin in the peripheral blood by no less than 1 min and no more than
2 min). Thus, at a lag interval of (+1, +2), insulin pulses in the portal
blood preceded those in the peripheral blood by no less than 1 min and
no more than 2 min (right side of graph). The expected number of
purely random coincidences was calculated via the hypergeometric
probability distribution in both the basal and stimulated states (in¬
terrupted lines). The observed number of coincidences significantly
exceeded expectation values at 1- to 3-min lag times, wherein portal
insulin pulses appeared first. The maximal coincidence was 13 events
in the basal state, and 17 events in the stimulated state. The corre¬
sponding expected values were 9 and 11 given the different pulse
frequencies at these times, with respective P values less than 10-5.
with type 2 diabetes (23), it is likely that the liver in these
patients is exposed to even more attenuated oscillations in
insulin pulse amplitude, which may contribute to the hepatic
insulin resistance characteristic of this disease (24).
The remarkable transhepatic attenuation of the insulin
pulse signal from the portal circulation to the systemic cir¬
culation observed here is comparable to that observed pre¬
viously in the dog (5). Although the attenuation may reflect
up to an approximately 4-fold dilution of portal venous
blood by the systemic venous drainage, the insulin pulse
amplitude is damped to a much greater extent than this
(~10-fold). One potential explanation for this is preferential
hepatic insulin clearance of insulin pulses. We previously
noted that the hepatic clearance of portal vein insulin in the
dog is related in an ascending monotonic (quadratic) manner
to the pulse amplitude of the insulin concentrationwavefront
presented to the liver (25). Taken together, these preliminary
observations provoke the need for additional studies to ad¬
dress this possibility of a link between pulse waveform and
hepatic insulin clearance. In one prior study in which blood
was sampled from the portal vein of patients with cirrhosis,
comparable large oscillations in insulin concentration were
observed, although no quantification of pulsatile insulin re¬
lease or corresponding arterial sampling was available (26).
In summary, direct sampling from the portal vein in hu¬
mans establishes an insulin interpulse interval of about 5 min
and thereby resolves the discrepant insulin pulse frequency
previously reported in humans. A comparable insulin inter¬
pulse interval can also be detected by high frequency pe¬
ripheral sampling with the use of a highly sensitive insulin
assay and appropriately validated pulse detection. Direct
portal vein sampling is consistent with prior studies in dogs
and humans, which reported that the majority of insulin is
secreted in insulin bursts. Finally, we confirm that the liver
in humans, like that in dogs, is exposed to dramatic insulin
concentration oscillations that far exceed themagnitude eval¬
uated to date in clinical studies of insulin action in vivo.
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Transjugular intrahepatic portosystemic stent-shunt
insufficiency and the role of diabetes mellitus
Syed H. A. Shah3, Hock F. Luia, Rajiv Jalan3, Ahmed Helmy3,
Doris N. Redheadb, Kay Penny0 and Peter C. Hayes3
Background/aims Maintenance of long-term patency of
transjugular intrahepatic portosystemic stent-shunts
(TIPSS) has proved problematic. Various prognostic
variables have been assessed as predictors, but the role of
diabetes mellitus, which induces vascular endothelial cell
dysfunction, has not been assessed.
Methods We analysed the records of 248 patients who
underwent TIPSS between July 1991 and July 1997,
followed-up through to August 1998. Patients with at least
one shunt assessment by portography and available blood
glucose levels were eligible (177 patients; median follow-
up, 15.0 months). Fourteen patients had a pre-procedural
diagnosis of diabetes (one insulin dependent, seven oral
hypoglycaemic treated and six diet controlled). In another
14 patients, diabetes was diagnosed at TIPSS insertion,
giving a 28/177 (15.8%) prevalence of diabetes in our
patients. Fifty-nine patients were excluded from the final
analysis (including five diabetics), as they either died or
had early shunt insufficiency (within 1 month of stent
placement), leaving 118 patients (including 23 diabetics) to
be. included In the final analysis.
Results Mean age, sex distribution, median follow-up
(months) and pre-shunt portal pressure gradient were
comparable in the two groups (diabetics versus non-
diabetics). Child-Pugh classes A and B were more
common in the diabetic group (P< 0.01), and the mean
inserted stent diameter was larger in the diabetic group
(P< 0.05). The presence of diabetes was associated with a
higher incidence of delayed shunt Insufficiency (P= 0.02),
but there was no evidence of an association between
presence of diabetes and variceal haemorrhage post
TIPSS. Kaplan-Meier analyses revealed earlier
insufficiency in diabetic patients compared with those
without diabetes (P= 0.04). Age, gender and presence of
diabetes are included In the final logistic regression model.
Individuals who have diabetes are more likely to
experience shunt insufficiency independent of age and
gender.
Conclusions Diabetes mellitus is common in patients
undergoing TIPSS and is associated independently with
increased incidence of primary delayed shunt insufficiency.
EurJ GastroenterolHepatol 13:257-261 ©2001 Lippincott
Williams & Wilkins
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Introduction
Transjugular intrahepatic portosystemic .stent-shunt
(TIPSS) is an effective method of treating portal hyper¬
tension and its complications [1], However, shunt
insufficiency and occlusion arc major limiting factors in
the success of this form of treatment [2]. Primary shunt
patency at 6 months, and I and 2 years has been
reported as 71.2, 58.2 and 21.4%, respectively [3], Rates
of shunt insufficiency in other studies have been shown
to vary from 25 to 80% [4-9]. Shunt stenosis can
usually be treated by balloon angioplasty, extension of
the stent or the insertion of a co-axial stent, but
reocclusion occurs [ 10.111.
0954 - 691X 2001 Lippincott Williams & Wilkins
The pathogenesis of shunt stenosis is not entirely clear.
One of the factors determining this is the time course
of occlusion. While early occlusion is associated with
thrombosis, delayed shunt dysfunction is predominantly
due to pseudo-intimal hyperplasia within the shunt
[12]. A number of factors have been assessed as
predictors of shunt insufficiency [13] and biliary venous
leak in the shunt lumen is also implicated [10].
Diabetes mellitus is common in patients with cirrhosis
of the liver [141. It leads to smooth muscle cell
proliferation and endothelial cell dysfunction in blood
vascular wall, especially the systemic arterial bed [ 15].
Similar mechanisms might be operative in the portal
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vascular bed in portal hypertension and thus may be
responsible for delayed shunt insufficiency due to
pseudo-intimal hyperplasia in patients who have had
TIPSS.
Patients and methods
The cohort of patients (« = 248) who underwent
TIPSS insertion between July 1991 and July 1997 was
reviewed, looking for shunt dysfunction post-TIPSS
and its relation to diabetes mellitus.
Patients were included in the analysis if TIPSS inser¬
tion was successful, at least one portographic shunt
assessment was completed post-insertion, blood sugar
profile was available for a diagnosis of diabetes mellitus
to be made and early TIPSS insufficiency (within
1 month post-TIPSS) was absent. Patients were not
entered into the analysis if they had incomplete data,
portographic follow-up was not available, early TIPSS
insufficiency was present or hepatocellular carcinoma
was present.
One hundred and seventy-seven patients (71.4%) had
successful TIPSS' placement, and had blood sugar
profiles available for a diagnosis of diabetes mellitus to
be made or excluded up to the time of TIPSS
insertion. Fifty-nine patients were excluded because of
either early death, early shunt insufficiency, referral for
portosystemic shunt surgery or liver transplantation
within the first month following TIPSS insertion. The
clinical data of the 118 patients who were entered into
the final analysis comparing diabetic versus non-dia¬
betic patients are presented in Table 1. TIPSS inser¬
tion was undertaken according to the method described
elsewhere [6]. The procedure was carried out under
sedation and analgesia with local anaesthesia, unless
general anaesthesia was indicated because of the clin¬
ical condition of the patient. Patients were followe.d-up
by Doppler ultrasound at day 7 post shunt placement to
exclude early thrombosis. Regular follow-up by porto¬
graphy was undertaken at 6-monthly intervals unless
shunt occlusion was clinically suspected, which led to
earlier portographic shunt assessment.
Data were censored when the patient: (1) died, (2) had
documented shunt insufficiency, (3) had liver trans¬
plantation, or (4) portographic surveillance was discon¬
tinued.
Definitions
Primary shunt insufficiency (PSI) was defined as the
increase in portal pressure gradient (PPG) to
> 12 mmHg [16] or an increase in portal pressure
greater than 20% from baseline, when the baseline
post-TIPSS portal pressure was above 12 mmHg [3,6].
PSI was further classified into early (< 1 month post
shunt placement) and delayed (> 1 month post shunt
placement). Diabetes was either diagnosed on oral
glucose tolerance test or on the basis of two random
blood glucose levels > 11 mmol/1 taken 6 months apart
(World Health Organization criteria). Rebleeding was
defined as overt haematemesis and/or melaena, or a
drop of haemoglobin of greater than 2 g/dl without any
other demonstrable source of blood loss or haemolysis.
Endoscopy confirmed gastro-oesophageal variceal bleed
or portal hypertensive gastropathy.
Statistical analysis
The statistical analysis was carried out using the
Statistical Package for Social Scientists software (SPSS
Inc. Chicago, Illinois). In order to compare risk factors
for shunt insufficiency in the diabetic and non-diabetic
patients, univariate testing was first carried out. /-Tests
were used to compare mean age, pre-shunt PPG and
post-shunt PPG, in the two groups of patients. Non-
parametric Mann-Whitney tests were performed to
compare length of follow-up and shunt-diameter in the
two groups, and chi-square tests were performed to test
for associations between presence of diabetes, gender,
Child's class, primary delayed insufficiency and variceal
haemorrhage.
In order to determine which factors were indepen¬
dently associated with primary delayed insufficiency,
logistic regression modelling was carried out. Several
clinical and biological variables were considered for
Table 1 Comparison of clinical data and shunt characteristics in diabetic versus non-diabetic patients
(n = 118) undergoing TIPSS with no demonstrable early shunt insufficiency
Factor Diabetic (n = 23) Non-diabetic (n = 95) P value
Age in years (mean ± SD) 57.3 ±11.2 52.2 ± 12.5 0.07
Gender (males/females) 18/5 57/38 0.15
Child's Class (A + B/C) 20/3 54/41 0.01
Follow-up (months) (median; IQR) 15.0, 22.0 17.2, 18.2 0.43
Pre-shunt PPG (mmHg) (mean ± SD) 19.6 ± 5.5 19.2 ± 7.0 0.79
Post-shunt PPG (mmHg) (mean ± SD) 8.5 ± 4.0 6.8 ± 4.6 0.1 1
Stent diameter (mm) (median; lower quartile, upper quartile) 12.0; 12.0, 14.0 12.0; 10.0, 12.0 0.02
Stent diameter (mm) (mean ± SEM) 1 2.2 ± 0.32 11.44 ± 0.16 0.04
SD, standard deviation; IQR, interquartile range; SEM, standard error of the mean.
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inclusion in the model, including age, gender, Child's
class, shunt diameter, pre- and post-shunt PPG, and
whether the patient had diabetes. The final logistic
regression model includes a subset of variables that are
significantly associated with delayed PSI, independent
of the other factors also included in the model.
Kaplan-Meier survival analysis was used to compare
time to delayed shunt insufficiency and a log-rank test
was applied to check for statistical significance of the
difference.
Results
Diabetes was present in 28 out of 177 (15.8%) patients
who had both successful TIPSS and blood sugar
profiles. Of the 118 patients who met inclusion criteria,
23 (19.5%) patients were diabetic and 95 (80.5%) non-
diabetic. Statistical testing provided no evidence that
the diabetic patients and non-diabetic patients differed
in age, sex, pre-shunt PPG, post-shunt PPG and length
of follow-up (Table 1). However, the presence of
diabetes was found to be associated with a better
Child's class (P = 0.01); diabetic patients were more
likely to have a Child's class A or B (87.0%) than non-
diabetics (56.8%). The median inserted shunt dia¬
meters were equal in the two groups, but the inter¬
quartile ranges showed diabetics to have larger shunts
in place (P = 0.02).
A comparison of clinical and demographic features
Detween the study sample and the entire TIPSS
treated population is presented in Table 2 and confirms
the representative nature of the sample in comparison
with the TIPSS patient population from which it is
derived.
The frequency of delayed PSI in diabetic versus non-
diabetic patients is presented in Table 3. Diabetic
patients were more likely to suffer from primary
delayed insufficiency (87.0%) than non-diabetic pa¬
tients (60.0%). This is unlikely to be due to a differ¬
ence in Child's classes among the two groups as the
incidence of shunt insufficiency is similar in Child's
classes A and B compared with C (Table 4). There was
no evidence of an association between the presence of
diabetes and variceal haemorrhage post shunt insertion.
Cumulative rate of diagnosed shunt patency is pre¬
sented in Figure 1, which shows significantly reduced
patency rates over time in diabetic patients with
cirrhosis of the liver (P = 0.04).
Table 5 presents odds ratios (ORs) and 95% confidence
intervals (CIs) for the factors included in the final
logistic regression model. These factors are statistically
significant when included in the model, and are inde¬
pendently associated with delayed shunt insufficiency.
Females are more likely than males, and diabetics are
more likely than non-diabetics, to experience shunt
Table 2 Comparison of clinical data and shunt characteristics of
the study sample versus the whole group of TIPSS treated
patients"
Study sample Total TIPSS treated
Factor (n = 118) patients (n = 248)





Oesophageal varices 75 155
Gastric varices 19 40
Ascites 16 36
PHG 3 6
Oesophageal + rectal varices 3 8
Hydrothorax 2 3
Aetiology of liver disease
Alcoholic cirrhosis 81 161
Cryptogenic cirrhosis 5 21
PBC 10 19
Post-hepatitic cirrhosis 12 20








A + B 65 115
C 53 133
independent samples f-test and chi-square test were applied to test for
association between the two groups and the P value was found to be not
significant in comparing different factors.
SD, standard deviation; PHG, portal hypertensive gastropathy; PBC, primary
biliary cirrhosis; PSC, primary sclerosing cholangitis; CAH, chronic active
hepatitis.
insufficiency (OR = 3.44, 95% CI = 1.37-8.61; OR =
7.30, 95% CI = 1.87-28.43, respectively). However,
individuals aged 55 years or over are less likely than
those in the younger age group to experience shunt
insufficiency (OR = 0.40, 95% CI = 0.17-0.94).
Discussion
This study included a large cohort of patients with
TIPSS who underwent long-tqrm portographic follow-
up. Diabetes has been shown to be associated with
increased prevalence of stent occlusion following cor¬
onary balloon angioplasty and stent implantation [16-
20]. If restenosis is viewed as an intraluminal growth
process after vascular injury, a similar mechanism might
be operative in TIPSS occlusion as in coronary stent
occlusion. Although there are haemodynamic differ¬
ences between the high-pressure arterial circulation in
the coronary circulation and the low-pressure portal
venous circulation, the turbulent flow in the TIPSS,
especially at the hepatic venous end of the stent (where
pseudointimal hyperplasia is most marked), makes it
liable to injury from stress of the jet stream of blood.
The process of repair and endothelial regeneration,
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Table 3 Outcomes in diabetic versus non-diabetic patients followed-up for primary
delayed insufficiency
Factor Diabetic (n = 23) Non-diabetic (n = 95) P value
Primary delayed insufficiency 20 (87.0%) 57 (60.0%) 0.02
Variceal haemorrhage 4 (17.4%) 12 (12.6%) 0.52
Post-TIPSS hepatic encephalopathy 4 (17.4%) 12 (12.6%) 0.52
Table 4 Primary delayed shunt insufficiency and variceal
haemorrhage in relation to Child's class of liver disease
Child's Class A + B Child's Class C P value
Outcome (n=71) (n = 47)
Primary delayed insufficiency 51 (71.8%) 26 (55.3%) 0.16









10 20 30 40 50
Follow-up period (months)
60
Cumulative rate of primary shunt patency compared in diabetic (dotted
line) versus non-diabetic (solid line) cirrhotics (P = 0.04).
Table 5 Final logistic regression model of primary delayed shunt
insufficiency
Factor Number of subjects Odds ratio (95% CI) P value
Diabetes
Non-diabetic 95 1.00 < 0.01
Diabetic 23 7.30 (1.87-28.43)
Gender
Male 75 1.00 < 0.01
Female 43 3.44 (1.37-8.61)
Age
< 55 years 61 1.00 0.04
> 55 years 57 0.40 (0.17-0.94)
ciated with increased prevalence of delayed PS1 (Table
4), and larger diameter stents in diabetic cirrhotics
would have made them less liable to occlude. Further¬
more, all factors in Table 1 were considered for
inclusion in the logistic regression model, and Child's
class and shunt diameter were not independent risk
factors.
Table 2 demonstrates that, although the study sample
is only »=118 (47%) of the entire TIPSS treated
group, it is still comparable with and representative of
the latter in its clinical and demographic features. The
number of patients who underwent placement of
TIPSS as an emergency and those with Child's grades
A and B were proportionately slightly greater in the
study sample as compared with that in the entire
TIPSS treated population, but that did not achieve
statistical significance. Although different complications
of portal hypertension from liver diseases of varied
aetiology led to treatment with TIPSS, the most
commonly treated entity in our centre was bleeding
oesophageal varices due to alcoholic cirrhosis.
The lack of evidence of an association between variceal
haemorrhage post shunt occlusion and the presence of
diabetes is surprising but may be due to the close
follow-up in our patients that allowed early interven¬
tion. Some of the patients also underwent endoscopic
band ligation after TIPSS, which would reduce the risk
of bleeding.
On post-TIPSS follow-up, hepatic encephalopathy
developed for the first time in 4/23 (17.4%) diabetic
cirrhotics (Table 3) and needed standard therapeutic
measures to be instituted. Although this was a higher
incidence than in the non-diabetic patients, it was not
statistically significant. The precipitation of encephalo¬
pathy did not follow episodes of gastro-intestinal bleed¬
ing and two patients each had Child's grades B and C,
respectively.
which may result in pseudointimal hyperplasia and
shunt insufficiency, follows this.
In our study population, the diabetic and non-diabetic
groups were comparable in their clinical characteristics
except for Child's class and stent diameter. Child's
class was better and larger stents were used in the
diabetic group. Child's class, however, was not asso¬
'
1 'his is the first study looking at the role of diabetes
mellitus, and occlusion and insufficiency of TIPSS. Our
results indicate that the presence of diabetes is asso¬
ciated with delayed shunt insufficiency, independent of
age and gender. Further work needs to be carried out
to determine if this may be a possible causal effect.
Hyperglycaemia induces alterations of growth factor
secretion [15|, which may be important in the genesis
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of shunt narrowing due to fibrous tissue and endothelial
overgrowth. The role of factors such as insulin-like
growth factor (IGF-1), transforming growth factor beta
(TGF-P) and endothelins (which have increased ex¬
pression and secretory rates in individuals with diabetes
and hyperglycaemia [21-23]) in smooth muscle cell
replication and pseudo-intimal hyperplasia in the shunt
lumen should be investigated. From a practical stand¬
point, the results of this study would suggest that
patients should be screened for diabetes at shunt
implantation and a meticulous glycaemic control main¬
tained post-TIPSS to prevent hyperglycaemia, and
therefore hopefully minimize delayed shunt insuffi¬
ciency.
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NOS INHIBITION DOES (NOT ALTER ADRENOCEPTOR-
MEDIATED CONTRACTION OF HUMAN HEPATIC ARTERIES, //V
VIIRO. S.H.A. Shah. M.Z. Islam. K.K. Madhavan1. P C. Haves and P.W.F
Hadoke. Liver. Research Unit and 'Scottish Liver Transplant Unit. Royal
Infirmary. Edinburgh. Scotland. U.K.
Background: Generation of nitric oxide (NO) by the inducible form ofNO
sy nthase (iNOS) in vascular smooth muscle cells may contribute to impaired
contractile function in patients with cirrhosis. This remains controversial,
however, as studies of isometric contraction in arteries from patients and
animals with cirrhosis have produced conflicting results.
Aims: This investigation aimed to determine whether the release of NO from
vascular smooth muscle cells modulates a-adrenoceptor-media£ed contraction of
hepatic arteries from patients with cirrhosis.
Methods: Hepatic arteries were obtained from recipients (cirrhotic: n=9) and
donors (non-cirrhotic; n=8) during orthotopic liver transplantation for in vitro
measurement of isometric contraction. Tw o rings, 2mm in length, w ere taken
from each artery and suspended in parallel in modified Krebs -Henseleit solution
at 37'C. perfused with 95% 0y 5% CCK Rubbing the luminal surface of each
vessel ensured removal of the endothelium. One ring from each artery was
incubated with the NOS inhibitor N0-mtro-L-arginine (L-NNA; 1()^M) whilst
the other was incubated with its inactive isomer( D-NNA; lO^M). Cumulative
concentration-response curves were obtained using phenylephrine (PhE: 10 "-
3x1O^M) and KC1 (2.5-120 mM).
Results: PhE (and KC1: data not shown) produced contractions of similar size
and sensitivity (pD:) in artcnes from cirrhotic (9.33±I.09g and 5.26±0.22.
respectively) and non-cirrhotic (10.46±l.71g and 5.67±0.31 respectively)
subjects. Incubation of vessels with L-NNA did not alter the response of either
donor or recipient arteries to PhE (Table 1).
Table 1. Recipient Hepatic Artery (a=9) Donor Hepatic Arten ( n=8)
1J-NNA I.-NNA P D-NNA I.-NNA /'
M.C l«) y.3±i. i 11.511.2 0.2! 10.511.7 11.211.8 0 75
ivt.C.f%k.Ch 120.41! i.2 122.0115.7 0.77 161.4119.6 167.0121.2 0 81
pl> 5.310.2 5.610.2 0.25 5.710.3 5.OKU 0 8L
Conclusions: These results indicate that the release of NO from the smooth
muscle cells of the hepatic artery does not modulate a-adrenoreceptor-mediatcd
contraction in patients with cirrhosis.
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